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Mouse models are widely used in pharmacology, yet the expression profile of the 
murine drug metabolizing enzymes has only begun to be characterized at the 
protein level. We developed a quantitative, high-throughput mass spectrometric 
method to measure the protein expression of the cytochromes P450 (Cyps) in 
tissue lysates isolated from Balb/c mice.   Global mass spectrometry-based 
proteomics revealed 27 proteins belonging to Cyp subfamilies 1a, 2a, 2b, 2c, 2d, 
2e, 2f, 2j, 2u, 3a, 4a, 4b, 4f, and 4v were readily detectable in Balb/c mouse 
tissue.  Using this protein list, a selected reaction monitoring mass spectrometric 
screen was developed to quantify expression of these 27 proteins.  The screen 
was applied to mouse liver microsomes and tissue lysates of kidney, lung, 
intestine, heart and brain from mixed sex fetuses; 3-4 weeks, 9-10 weeks, and 8-
10 months of age male and female mice; and pregnant mice.  All 27 proteins 
were identified in liver microsomes. Cyps were identified in all lysates, including 
10 in kidney, 15 in lung, 8 in intestine, 6 in heart, and 4 in brain.  Liver 
microsomes differed in expression with sex, age, and pregnancy.  Cyps 1a2, 
2c67, and 4a12a appeared to be more abundant from male mouse livers of all 
ages.  Hepatic expression of Cyp2b9 was more abundant in 3-4 week old mice in 
comparison to mice of other ages, and it was the only enzyme identified in higher 
abundance in pregnant mouse microsomes in comparison to the age matched 
females.  Sexually dimorphic expression appeared exclusively in kidney for Cyps 
2b9, 2d26, 2e1, and 4b1. Microsome activity experiments evaluated the mouse 




efavirenz, revealing differences in metabolite formation with age, sex, and 
pregnancy status.  Collectively, these data provide a foundation for the use of 
mice as a preclinical model for understanding Cyp pharmacology and contributes 
to a wider understanding of mouse xenobiotic metabolism. 
In a second set of experiments, a derivatization technique of unmodified lysine 
residues on histones is used in combination with high performance mass 
spectrometry to distinguish and quantitate endogenously acetylated isoforms 
occurring within the same tryptic peptide sequence and to extend this 
derivatization strategy to other post-translational modifications, specifically 
methylation, dimethylation and trimethylation. The in vitro deuteroacetylation of 
monomethylated lysine residues is observed, though dimethylated or 
trimethylated residues are not derivatized. Comparison of the relative intensities 
ascribed to the deuteroacetylated and monomethylated species with the 
deuteroacetylated but unmethylated analog, provides an opportunity to estimate 
the percent of methylation at that site. In addition to the observed fragmentation 
patterns, the very high mass accuracy available on the Orbitrap mass 
spectrometer can be used to confirm the structural isoforms, and in particular to 
distinguish between trimethylated and acetylated species. 
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“Proteomics” is the global study of cellular proteins.  Of the four types of different 
macromolecules, including proteins, lipids, carbohydrates and nucleic acids, 
proteins are the primary mediators of cellular activity (Tyers & Mann, 2003).  
Proteins are involved in structural organization, signaling between cellular 
compartments, and enzymatic reactions to chemically change another molecule.  
They work together through associations and conformational changes and can 
be regulated by protein-mediated transcription/translation, degradation, or 
modification (Tyers & Mann, 2003).  Probing cellular dynamics as a whole protein 
network offers a more complete view of cellular interactions and activity (Clancy 
& Hovig, 2013; Tian, 2013). Currently, many “-omics” fields are devoted to global 
research using high-throughput methodology, a trend which began with 
“genomics” in the 1980’s (Kuska, 1998).  Once the genome was published, 
theoretical proteins could be transcribed electronically “in silico.”  Global 
discovery of proteins using mass spectrometry is now well-established using the 
genome databases, and now the focus is on the direction of biology (Ahmad & 
Lamond, 2013).  Researchers are applying proteomics to technically challenging 
projects such as the quantification of highly modified proteins or highly similar 
proteins. 
Proteins are globular molecules made from multimers of amino acids.   All 20 
amino acids have the formula R-CH(NH2)COOH, where the amine and the 
carbonyl group form a  polar protein backbone. The R group can be acidic, basic, 
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nonpolar, small (56 Da) or large (186 Da), each denoted by a single letter for 
simplicity in recording their sequence.  The sequence is listed from the amino-
terminus (Waterston et al) to the carboxy terminus (C-).  Some R-groups, for 
example lysine (K) and arginine (R), can be modified in the cell to receive a 
“post-translational modification”, for example acetylation (-COCH3) or methylation 
(-CH3).  The protein is composed of a sequence of residues, which reflects the 
function of the protein.  For example, the residues exposed to cytosol are 
typically hydrophilic and the residues in the protein core are more hydrophobic 
(Jager et al, 2008).  Histones have a hydrophilic tail containing many lysine and 
arginine residues which are available to cellular enzymes for modification in 
addition to a hydrophobic core.  In contrast, cytochrome CYP enzymes are 
embedded in the endoplasmic reticulum membrane and their function requires 
nonpolar substrates to diffuse into the active site, which is reflected in their 
sequence.  The type and sequence of residues in a protein are unique, which 
underlies the power of proteomics and contributes to its technical challenges.  In 
a typical proteomics analysis, proteases digest the protein into peptides an 
appropriate size for determining the sequence.  The most commonly used 
protease is trypsin, which cleaves the amide peptide bond on the carboxyl side of 
the basic amino acid residues lysine and arginine (Olsen et al, 2004).  
Proteolysis by trypsin typically yields peptides ranging from 200-4000 Da, which 
are small enough to be detected by high resolution mass spectrometry and which 




Mass spectrometry identifies the masses of molecules in a sample.  The 
instrument induces a charge on the molecule by gain or loss of a hydrogen ion, 
and the subsequent ions are controlled by electrostatic forces in the instrument.  
As ions move towards an opposite charge, the acceleration is a function of the 
mass to charge ratio (m/z).  Larger molecules change their movement more 
slowly than smaller molecules of the same charge, and in this way, the 
movement of the ions is indicative of the mass.  Mass spectrometers usually 
include a mechanism for isolating and breaking an analyte (“parent compound”) 
into multiple fragments (“transitions”).  The experiments in this thesis use a 
fragmentation method called collision induced dissociation (CID) whereby an 
inert gas such as nitrogen or helium is introduced into the vacuum.  Multiple 
collisions impart enough vibrational energy within the peptide to break the 
backbone. The half of the fragment that receives the charge is subsequently 
controlled by the optics of the instrument for later detection.  The fragment can 
either be the N-terminal fragment (b-ion) or the C-terminal fragment (y-ion).  The 
process of collecting a mass spectrum from the parent and then from a fragment 
is called MS/MS.  The MS/MS spectrum is considered to be the fingerprint for 
identification of the analyte. Instruments differ in the particular combination of 
method of ionization, ion separation, and detection systems.  The time of flight, 
Orbitrap, and triple quadrupole used in this research are discussed below. 
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The time of flight (TOF) instrument detects m/z based on separation in a vacuum 
and the arrival time of the ions at the detector (Cotter & American Chemical 
Society. Meeting, 1994).  The TOF imparts an extraction potential at the site of 
ionization so that oppositely charged ions accelerate toward it.  The potential 
applies the same amount of force on all ions, but the larger molecules accelerate 
more gradually and therefore travel with less velocity.  Ions continue their 
momentum down the flight tube.  A detector records the abundance of ions as a 
function of time with the time of flight as the indicator of mass.  Sensitivity can be 
as low as a single molecule, depending on the TOF instrument.   The distribution 
of ions is disproportional such that molecules with low molecular weight have 
high velocities and overlapping arrival times whereas molecules of higher 
molecular weights are readily distinguished.  Many TOF mass spectrometers 
incorporate a curved field reflectron to accomplish four-fold higher resolution 
(20,000 FWHM) while maintaining a high mass range of 80 kDa 
(ShimadzuBiotech, 2006). This technique is often paired with a solid sample 
ionization method called Matrix Associated Laser Desorption Ionization (MALDI).  
It employs a matrix such as alpha-cyano-4-hydroxycinnamic acid to stabilize the 
sample and to impart a charge.  The dried sample-matrix spot is shot with a soft 
337nm laser, which imparts enough energy to vaporize the analyte for detection 
in the mass spectrometer.  Molecules of a known weight are used to calibrate the 
time of flight to the m/z.  Resolution and accuracy are most affected by variable 
travel distance to the end of the extraction region.  While a thick sample 
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deposition or a large distance between the positions of the reference sample to 
the experimental sample on the sample plate can noticeably alter resolution and 
accuracy, this method is nevertheless popular for analysis of a relatively simple 
mixture, especially for labile modifications and larger peptides and proteins.   
In 2000, the invention of the Orbitrap allowed high resolution analysis of many 
ions simultaneously (Makarov, 2000).  The Orbitrap is composed of a metal rod, 
a nearly seamless metal casing, and a vacuum area between all about 1.5 
inches wide and 1 inch tall.  Ions are injected into the Orbitrap in a packet.  The 
ions enter the Orbitrap in a trajectory to fly past the rod, but the charged rod 
attracts the ions such that they go into a stable orbit.  The rod is thinner on the 
ends than in the middle of the chamber.  This shape forces ions that reach the 
end to move back towards the middle.  As the ions are orbiting they have a 
characteristic frequency of movement from one side of the rod to the other.  The 
movement of ions in orbit creates an electromagnetic signal.  The total signal 
strength as a function of time can be deconvoluted by Fourier Transform (Muller 
et al) into a frequency signal from each ion.  The frequencies are calibrated to 
known masses using reference molecules.  Resolution from an Orbitrap is 
among the highest available at up to 100,000, as in the LTQ OrbitrapXL used in 
this research (and 240,000 in the most recent models)(ThermoFisherScientific, 
2009b).  The mass range is sufficient only for small molecules, peptides and 
small proteins at 50-5000 m/z. Orbitrap instruments are most frequently paired 
with an electrospray ionization source (ESI).  ESI uses high voltage to vaporize 
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compounds in the liquid phase emitted from capillary, which is convenient for 
complex peptide mixtures and high-throughput analysis.  In the work presented 
here, a high performance liquid chromatography (HPLC) in tandem with an 
Orbitrap Velos allows a complex peptide mixture to be separated based on 
hydrophobicity in sixty to ninety minutes per sample.  A data-dependent MS/MS 
analysis is performed throughout the liquid chromatographic analysis.  The “data” 
of the data-dependent analysis is a spectrum collected from the mix of parent 
compounds at high resolution in the Orbitrap.  From these data, a single peak 
width of m/z is isolated and fragmented, and a spectrum of the mix of fragments 
is collected in the Orbitrap.  The set of spectra produced from all peptides in a 
liquid chromatographic analysis can be submitted to the Mascot search engine to 
find matches in peptide masses and expected fragments.  This software, the 
data-dependent MS/MS, the sample separation by liquid chromatography, and 
the high resolution and the simultaneous detection of peptides have become the 
standard for high throughput peptide and protein identification.  
The triple quadrupole mass spectrometer is designed for selectivity and 
sensitivity (Hopfgartner et al, 2004).  It is characterized by three sequential 
chambers that select a peptide, fragment the peptide, and select for a specific 
fragment.  Each chamber consists of four parallel rods.  Two opposing rods are 
positively charged and the other two rods are negatively charged.  To keep the 
ions trapped, the rods switch polarity, inducing the ions to oscillate in the vacuum 
chamber.  In addition to the polarity switching, a radio frequency voltage 
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(oscillating in intensity) can be applied to the rods.  The oscillation frequency of a 
particular mass ion resonates with the radio frequency of the rods, causing that 
ion to increase in energy until it ejects itself from the chamber.  With sequential 
ejections, a particular peak m/z can be isolated and retained in the quadrupole 
chamber.  This isolation is performed up to two times: to isolate the parent and to 
isolate the fragment.  A high number of ions in the instrument lowers sensitivity 
due to charge interference.  Elimination of all molecules except at the m/z of 
interest increases sensitivity.  In addition, the double selection allows for more 
confidence in the identity of the analyte.  Triple quadrupole mass spectrometers 
are typically interfaced with HPLC sample separation.  Data is frequently viewed 
as a chromatograph of the single parent/fragment isolation instead of a mass 
spectrum.  An example of a triple quadrupole mass spectrometer is the Thermo 
TSQ Vantage (ThermoFisherScientific, 2009a).  This instrument is used for high 
throughput quantitation of peptide abundance as well as abundance of small 
molecules such as drugs.  Quantitation of a peptide is often performed using an 
identical synthetic peptide that is 13C and 15N isotope labeled at a lysine or 
arginine residue.  These isotope labeled peptides will ionize with equal efficiency 
to the unlabeled analyte. The isotope label is spiked into the protein sample to 
standardize the sample preparation and the injection amount between the 
analyte and the isotope standard.  Quantitation is then performed by comparing 
the ratio of the area under the curve of the analyte to the isotope labeled 
standard and the calibration curve of standards to the amount of standard spiked 
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into the protein sample.  Alternatively, analyte peak area is compared to a 
calibration curve of a synthetic peptide that does not need to be labeled.  While 
the triple quadrupole instrument is the standard for quantitative experiments, it is 
slow and inefficient at discovery of proteins in a complex sample. Similar to the 
software developed specifically for the Orbitrap, open source software  “Skyline” 
has been developed for peptide analysis with triple quadrupole mass 
spectrometers, which facilitates peptide screening and quantitation of high-
throughput samples (MacLean et al, 2010).   
Some techniques are more readily accessible to biologists than mass 
spectrometry, including immunoblots and RT-PCR.  Immunoblots can be used for 
protein or post-translational modification identification or quantitation.  The 
technique can be very sensitive in a complex protein mixture, depending on the 
specificity of the antibody (Lee et al, 2000).  Antibodies can be made to be very 
specific or promiscuous for multiple similar proteins (Michaud et al, 2003).  In 
immunoblotting, the primary antibody binds the SDS-PAGE-resolved protein of 
interest and is detectable either directly, by conjugation to the enzyme 
horseradish peroxidase, or via conjugated secondary antibodies. The 
horseradish peroxidase on the antibody is then exposed to its substrate to create 
a fluorescent product only at the site of antibody binding.  The choice of proteins 
to probe is limited by the antibodies that are available.  Although the technique is 
costly in time and amount of sample if one is probing many proteins, the 
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technique is robust, inexpensive, and accessible to the traditional chemical 
biologist. 
Studying mRNA expression is high-throughput and inexpensive, so it has 
become the surrogate for studying cellular status (Suter et al, 2004). The 
polymerase chain reaction (PCR) technique requires mRNA extracted from fresh 
tissue and a complementary primer sequence, so that one mRNA molecule is 
amplified to a detectable amount.  Quantitation involves measuring the 
fluorescence intensity of the marker bound with the DNA products, compared to 
the fluorescence from tubes with known quantities of DNA.  PCR is simple, 
although it does require some special instrumentation and careful technique.  
The quality of data depends on the quality of the original sample, which is very 
sensitive to contamination by an enzyme, RNase. Although mRNA abundance 
contains a substantial amount of information regarding the activity status of a 
cell, few RNAs perform the cellular activity itself and can sometimes be poorly 
representative of cellular activity (Vogel & Marcotte, 2012). 
Cytochromes P450 
The cytochromes P450 (CYP) are a family of enzymes that metabolize 
endogenous and exogenous compounds through oxygenation.  Hydroxylated 
metabolites are more soluble and are more easily excreted.  Of all metabolized 
drugs, CYPs are responsible for metabolizing about 75% (Wienkers & Heath, 
2005). Each cytochrome P450 “isozyme” metabolizes multiple substrates. CYPs 
are located primarily on the endoplasmic reticulum, and they are unified by a 
11 
 
similar enzymatic mechanism for hydroxylation involving an iron-containing heme 
cofactor. Briefly, the donation of two electrons from two reductases and electron 
donors such as NADPH assist the CYP to activate the iron, then activate the 
oxygen molecule.  This activation results in a highly unstable intermediate, which 
reacts with the substrate resulting in an oxidized product. The name “P450” 
comes from “pigment” (P) because the enzymes are colored red due to the 
heme, and from the wavelength of radiation emitted (450 nm) when carbon 
monoxide binds to the heme group instead of oxygen.   
Activity of an enzyme can be determined in vitro by incubating enzyme with an 
energy source (NADPH) and substrate (Center for Drug Evaluation and 
Research (CDER)).  The enzyme can be made recombinantly to investigate the 
activity of a single isozyme, or it can be isolated from tissue microsomes.  
Microsomes are protein-containing vesicles enriched for endoplasmic reticulum.  
They are prepared by homogenization of the tissue and ultracentrifugation of the 
organelle fraction.  The resulting metabolites formed from the activity assay are 
analyzed for changes in their structure. 
Nomenclature is based on homology using numbers and letters to indicate 
family, subfamily, and isozyme (e.g. CYP1A2).  Family members exhibit greater 
than 40% sequence identity, subfamilies have greater than 59%, and isozymes 
represent gene clusters. Allelic variants have the same name if they are 97% 
identical.  It is convention to capitalize the subfamily letter for human enzymes 
and use lowercase for mouse enzymes (Nebert et al, 1989) (Nelson & Strobel, 
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1987).  For example, there exists a mouse Cyp1a2 and a human CYP1A2.  
Because they are within 97% homology the two isozymes have the same name 
except for the capitalization, which indicates the species of each allele.   
Despite mice serving as a drug metabolism model since 1940 (Lawrence et al, 
1940), mouse Cyps being studied since the 1960’s (Waterfield et al, 1969), and 
the genome being sequenced in 2002 (Waterston et al, 2002), the mouse Cyp 
proteome remains a mystery.  There are 102 putatively functional murine Cyp 
genes (Nelson et al, 2004).  Only recently has there been some proteomic 
characterization (using Orbitrap instruments) to determine which of these genes 
are expressed (Shinde et al, 2009; Sutton et al, 2010). Mouse Cyp research is 
otherwise limited to cross-reactivity of human protein-targeted antibodies, mRNA 
expression, and “knock-in” mouse models for human CYPs.   
Histones 
In the nucleus, the core histones H2A, H2B, H3 and H4 serve as a scaffold to 
wrap 146 basepairs of double-stranded DNA.  The DNA-histone complex is 
called a nucleosome (Luger et al, 1997). Each histone has two general domains: 
an inner core region and an exposed N-terminal “tail”, which can be post-
translationally modified with acetylation, methylation, phosphorylation or other 
modifications (Cheung et al, 2000). This post-translational modification (PTM) 
profile of histones is dynamic, constantly remodified by acetyltransferase and 
deacetylase enzymes or methyltransferases and demethylases, which are in turn 
tightly regulated (Bonisch et al, 2008).  Specific PTMs and combinations of PTMs 
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are proposed to function as a histone code that directs gene silencing, 
transcription, replication, cellular memory and gene recombination (Barlesi et al, 
2007; Bonisch et al, 2008; Su et al, 2007). Elucidating histone post-translational 
modifications has thus become essential to understanding epigenetics.  All 











Figure 1-1.  Reported human histone PTMs in the literature. (ac acetylation, 
me1 monomethylation, me2 dimethylation, me3 trimethylation, mex unspecified 
methylation number, P phosphorylation, ribo ADP ribosylation, ub ubiquitination, 
su sumoylation, bio biotinylation, iso proline isomerization, cit citrulination, but 
butylation).  N-terminal methionine is cleaved in the functional protein, therefore 
numbering starts at 1 for the first non-methionine residue.  Figure modified from 




Histones are acetylated by histone acetyltransferases and deacetylated by 
histone deacetylases on lysine residues.  Acetylation is correlated with 
transcriptional activation for example in younger populations.  Deacetylation of 
histones is generally correlated with transcriptional silencing. Lysines can receive 
either an acetylation or 1-3 methyl groups and arginines can receive up to two 
methyl groups.  Methylation typically acts as a repressor, but can also act as a 
transcriptional activator on certain histone residues.  Histones are methylated by 
histone methyltransferases and demethylated by demethylases.  
Methyltransferases are hyperactive in cancer, for example.  These and many 
other histone modifications represented in Figure 1-1 collectively contribute to 
chromatin regulation in the nucleus.  Modification patterns of histones differ 
between species (Garcia et al, 2007a).  Histones are heavily studied because 
they serve a fundamental role in biology, however they pose a technical 
challenge for mass spectrometrists.   
A traditional “bottom up” proteomics method involves tryptic digestion of purified 
protein and analysis with mass spectrometry (Young et al, 2010). This technique 
assumes complete trypsinization and minimal lysine or arginine modifications for 
peptide quantitation.  The “top-down” or “middle-down” peptide identification 
strategies used by Kelleher et al. (Siuti & Kelleher, 2007), along with lysine 
derivatization methods described by Garcia et al. (Garcia et al, 2007b; Garcia et 
al, 2007d), use intact or longer sequences by direct fragmentation via electron 
capture dissociation on a Fourier Transform Mass Spectrometer (Boyne et al, 
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2006; Jiang et al, 2007; Siuti et al, 2006). It is assumed that the number and/or 
position of basic residues for the intact proteins will have minimal effect, 
compared with smaller structures, on their chemistry and therefore on the 
opportunities for relative quantitation of the different isoforms (Pesavento et al, 
2004; Young et al, 2009). Furthermore, all possible structural/positional 
combinations will be intact, hence hydrophilic interaction liquid chromatography 
can be combined with fourier transform mass spectrometer to identify and 
distinguish more than 150 differentially modified forms of histone H3.2 in HeLa 
cells using a top down approach (Siuti & Kelleher, 2007). This method is 
quantitative and the most biologically relevant, yet it is limited by the complexity 
of the sample and has been called impractical for histone PTM identification 
(Young et al, 2010).   
An alternative approach uses propionic anhydride to form propionyl analogs that 
differ in mass from the acetylated peptides by 14 Daltons and obviate the need for 
isotopic corrections to the relative abundances (Garcia et al, 2007c). This approach 
has been used in a two step derivatization process, carried out before and after 
tryptic digestion, in which the second derivatization carries a stable isotope d5 
analog to enable quantitative comparisons between two samples (Plazas-Mayorca 
et al, 2009).  The resulting peptides, however, produce dissimilar chromatographic 
behavior, ionization efficiency and quantitative accuracy. 
The method presented in this thesis research is based on an approach first 
introduced by Catherine Smith (Smith et al, 2003) using deuteroacetylation.  
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Smith and colleagues used a mixture of deuterated (d4) acetic acid and 
deuterated (d6) acetic anhydride as the derivatization reagent, converting all 
endogenously unmodified lysines present in the histone sample to 
deuteroacetylated species, with a mass shift of +45 Da (Smith, 2005; Smith et al, 
2003).  
Deuteroacetylation is an in vitro chemical reaction performed by mixing dried 
protein with a 5:1 mixture of deuteroacetic acid and the chemically reactive 
deuteroacetic anhydride, pictured in Figure 1-2.  The reaction occurs 
spontaneously over several hours: the nucleophilic histone lysine nitrogen 
attacks the carbonyl electrophile of a deuteroacetic anhydride molecule.  The 
nitrogen is then covalently deuteroacetylated with an inert deuteroacetic acid 
byproduct.    
The label-modified lysines are then chemically and chromatographically 
equivalent to their in vivo acetylated counterparts, but distinguishable by a three 
Dalton mass difference (+45 Da vs. +42 Da, respectively). All lysine residues are 
then equivalently “blocked” from cleavage by trypsin, cleavage occurs at arginine 
residues only, and the fragments generated are now larger in size, providing in 
some cases the ability to observe multiple modifications. From the mass spectra, 
three Dalton mass shifts are used to determine and quantitate endogenously 
acetylated (d0) and in vitro deuteroacetylated (d3) peptides. This technique is 
inexpensive, quantitative, high-throughput.  An experiment detailing the PTM 
analysis of an individual histone sample requires about two hours of instrument 
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time, and a similar time for the subsequent data analysis.  It provides high 
sequence coverage, site-specific PTM identifications, and accurate relative 











Figure 1-2. Deuteroacetylation tags all unmodified lysines with a 
deuteroacetyl group 3 Daltons heavier than endogenous acetylated lysines.   
Green bonds indicate endogenously formed bonds and black indicates in vitro 





In this thesis, I present the following contributions: 1) a proteomics SRM assay 
including 27 mouse cytochromes P450, 2) a semi-quantitative profile of mouse 
Cyp distribution in liver, kidney, lung, intestine, heart, brain, males of 3 ages, 
females of 3 ages, pregnant mice and fetuses, 3) characterization of efavirenz 
and its metabolites within the mouse model, including the effects of age, sex, and 
pregnancy status on metabolism, and 4) application of chemical derivatization for 





















Human CYP protein expression, mRNA expression, and CYP activity studies 
have revealed differences between tissue type, gender, age, and pregnancy 
status. For example, mRNA expression of a variety of human tissues 
demonstrates mainly hepatic expression of CYPs 1A2, 2C19, 2D6, and 3A4 
(Bieche et al, 2007).  Bieche et al. also identified predominant expression of 
certain Cyps in other tissues (e.g., CYP 2J2 in heart and 2F1 in lung).  Age-
dependent CYP expression has been described in immunoblotting studies, with 
perinatal expression of 3A7 and 2C9 and an increase in expression of 1A2, 2B6, 
2D6, and 2E1 from 9 days old to 28 years old (Tateishi et al, 1997).  One study 
employed an activity assay with human liver microsomes to identify a genetic 
basis for an apparent sex-dependent phenotypic discrepancy in CYP3A4 
(Schirmer et al, 2007). Human heterogeneity in genotype and lifestyle also cause 
variability in CYP mRNA expression, resulting in 40- to 500-fold differences for 
some CYPs (Rodriguez-Antona et al, 2001). Researchers have used humanized 
mouse models to study human CYPs in an effort to reduce inter-individual 
heterogeneity.  This approach enables the use of human CYP antibodies for 
protein detection, avoiding the need to raise antibodies to murine Cyps.  For 
example, human 2E1 was expressed in mouse liver to evaluate the role of 2E1 
induction in alcohol induced liver damage (Morgan et al, 2002).  
Mice are the canonical academic model for drug efficacy and pharmacokinetic 
experiments yet only limited research has been done to characterize 
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endogenous Cyp protein expression in these model systems.  A few prominent 
cases where murine Cyp proteins have been studied include Cyp2e1-null mice 
used to demonstrate a role for murine Cyp2e1 in high-fat mediated non-alcoholic 
steatohepatitis (Abdelmegeed et al, 2012) and Cyp4b1-null mice used to 
investigate its role in bioactivation of a pulmonary toxin (Parkinson et al, 2013).  
These experiments highlight the utility of murine Cyp mouse models for human 
disease and drug metabolism.  Further characterization of murine Cyp protein 
expression can serve to promote the functional, mechanistic and biological 
relevance of Cyps.  
To assess differences in protein levels in a more global high throughput fashion, 
we applied quantitative, targeted mass spectrometry to confidently detect a 
unique Cyp protein. SRM assays target dozens of peptides simultaneously with 
high specificity and sensitivity and can be applied to quantify proteins in any 
complex mixture.   
The emerging field of “pharmacoproteomics” is expanding the understanding of 
molecular drug metabolism and Cyp biology, which has previously been driven 
by mRNA expression profiling and Cyp activity assays.  Currently, less than a 
dozen publications apply mass spectrometry to Cyp protein biology.  They report 
protein identification lists ranging from 11-37 Cyps (Flint et al, 2010; Jenkins et 
al, 2006) depending on sample preparation, mass spectrometer speed and 
sensitivity, and rigor of analysis. Patterson et al. have used global proteomics 
methods and optimized microsome preparation to improve the number of Cyp 
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isozyme identifications and quantitation accuracy (Sutton et al, 2010). Others 
have used global proteomics methods to identify changes in Cyp expression in 
mouse liver in response to psychological stress and exposure to carcinogens 
(Flint 2010) or to quantify Cyp induction by exposure to phenobarbitone (Jenkins 
2006). 
A mouse model characterizing natural Cyp biology would be valuable for 
comparison with current mouse models for pharmacokinetic and in vivo drug 
distribution experiments. The natural biological variation of Cyp expression in 
healthy mice is unexplored.  To address this, we describe parallel Cyp 
proteomics and microsome activity assays.  We identified the murine Cyps 
expressed in Balb/c mouse tissues and developed a 27-protein quantitative mass 
spectrometry assay.  To characterize the influence of biological factors on Cyp 
expression, we applied the assay to liver, kidney, lung, intestine, heart and brain, 
from male and female mice at 3-4 weeks, 9-10 weeks, and 8-10 months of age.  
We found striking tissue specific expression differences, including the highest 
expression of cyp2b9 in the brain compared to other Cyps.  Cyps 4b1, 2e1, and 
2b9 showed a trend for higher expression in male kidney at all ages in 
comparison to female samples, whereas Cyp2d26 showed the opposite trend.  
The abundance of Cyps 4a10 and 4a12a correlated with age.  Fetal liver was 
found to express Cyp 2d26 most abundantly in comparison to other Cyps, and 
pregnant mouse liver microsomes contained less Cyp 2e1 than other adult mice.  
Furthermore, we used the drug efavirenz to observe Cyp activity differences with 
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age, sex, and pregnancy status.  These experiments allow direct comparison of 
proteomic results with activity of a sample xenobiotic substrate.  This global 
assessment of murine Cyp expression provides a thorough and unique insight to 
murine Cyp biology. 
 
Methods 
Chemicals and Reagents. Efavirenz was purchased from Toronto Research 
Chemicals (Toronto, ON, Canada). NADPH was purchased from BD Biosciences 
(San Jose, CA).  Iodoacetamide, phenylmethanesulfonyl fluoride, and urea were 
obtained from Sigma Aldrich (St. Louis, MO). Hexanes and Ethyl Acetate were 
purchased from Thermo Fisher Scientific (Sunnyvale, CA).  All other chemicals 
were of the highest grade commercially available.  
Mouse Tissue Preparation.  Liver microsomes were prepared from the livers of 
male and female mice 3-4 weeks, 9-10 weeks, and 8-10 months of age in 
addition to pregnant mice (10-12 weeks of age) and fetuses (gestation day 16).  
Mice were euthanized as approved by the Johns Hopkins University Animal Care 
and Use Committee. The liver was excised and homogenized in a 1:4 (w/v) ratio 
of buffer (100 mM Tris HCl pH 7.4, 100 mM KCl, 1mM 
ethylenediaminetetraacetic acid, and 1mM phenylmethylsulfonylfluoride).  The 
supernatant was filtered using a 70 μM nylon filter and tissue lysate was 
centrifuged at 10,000 x g for 30 minutes at 4°C. The supernatant was separated 
from cell debris then centrifuged at 10,000 x g for 30 minutes at 4°C.  
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Microsomes were isolated by ultracentrifugation at 100,000 x g, 4°C, for 90 
minutes. The resulting pellet was washed using 3 ml 100mM Sodium 
Pyrophosphate buffer, pH 7.4 and centrifuged at 100,000xg 4°C for 60 min.  
Finally, the microsomes were resuspended in 200 μl of 50mM KPO4 buffer, pH 
7.4 containing 0.1mM ethylenediaminetetraacetic acid, 0.1mM dithiothreitol, and 
20% glycerol.  Tissue total protein lysates were prepared from kidney, lung, 
intestine, heart and brain of the 10-12 weeks of age pregnant, 3-4 weeks, 9-10 
weeks, and 8-10 months of age male and female mice.  Fetal brain was the only 
other organ collected from fetus.  All fetal brains from the pregnant mothers were 
pooled and lysed. Tissue was homogenized in lysis buffer containing 20 mM Tris 
HCl pH 7.5, 150 mM NaCl, 1mM ethylenediaminetetraacetic acid, 1 mM ethylene 
glycerol tetraacetic acid, 1% Triton, 2.5 mM sodium pyrophosphate, 1 mM beta-
glycerophosphate, 1mM Na3VO4, 1 ug/ml leupeptin, and 1mM 
phenylmethylsulfonylfluoride (Cell Signaling, Danvers, MA).  Samples were 
centrifuged at 10,000 x g for 30 minutes at 4°C, and the supernatants were 
saved. The microsomes and lysates that were isolated from 4 individual mice 
within the same age and sex group were pooled.  Fetal liver microsomes and 
brain lysates from all pregnant mice were pooled. Protein concentration was 
determined using the BCA Protein Assay Kit (Thermo Scientific Pierce, Rockford, 
IL), and protein was frozen at -80°C until use.   
In-gel Peptide Isolation for Global Proteomics. Protein (25 μg) reduction and 
alkylation was performed in NuPAGE LDS sample buffer (Life Technologies, 
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Carlsbad, CA).  NuPAGE Reducing Agent (Life Technologies, Carlsbad, CA) was 
added (50 mM DTT) and heated 70°C for 10 minutes.  Samples were cooled to 
room temperature before incubation with of 1.2 μl of 1 M iodoacetamide (100 
mM) for 20 minutes in the dark.  NuPAGE Reducing Agent (80 mM) was added 
for continuation of the reaction for 20 minutes in the dark.  A 10% tris-glycine gel 
(Biorad, Hercules, CA) was prepared with 25 μg protein loaded in each well.  
NuPAGE Antioxidant (500 μl, Life Technologies, Carlsbad, CA) was mixed in the 
running buffer.  The gel was stained with SimplyBlue SafeStain (Life 
Technologies, Carlsbad, CA) according to manufacturer instructions.  The 45-62 
kDa band region of the gel was removed, corresponding to the range of 
molecular weights of murine Cyps.  The stain was removed from the gel by 
incubation for 2 hours with 200 mM ammonium bicarbonate and 40% acetonitrile.  
Gels were dried under vacuum and trypsinized at 1:20 trypsin:protein ratio for 18 
hours at 37°C.  The resulting peptide solution was removed and the gel was 
extracted with 0.1% trifluoroacetic acid, 50 mM Ambic, and 50% acetonitrile by 
incubation at 37°C for 1 hour.  Extracted peptides of each sample were combined 
with peptides for drying.  Samples were reconstituted in 10μl of mobile phase A, 
2 μl of which were injected for each LC-MS analysis. 
Global Proteomics LC-MS Assay. Protein discovery experiments were 
performed by The Mass Spectrometry and Proteomics Facility at Johns Hopkins 
School of Medicine.  Balb/c 9-10 weeks of age male and female tissue lysates 
(n=1) were analyzed to generate a list of proteins expressed in Balb/c mice.  An 
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Eksigent nano 2-D HPLC was used in tandem with the high resolution Orbitrap 
Velos mass spectrometer (Thermo Scientific, Sunnyvale, CA).  Peptides were 
separated on an in-house 10 cm column packed with 5 μm Magic C18 beads 
(Michrom Bioresource, Auburn, CA). Gradient solvents were composed of 2% 
acetonitrile 0.1% formic in LCMS grade water (Solvent A) and 90% acetonitrile 
0.1% formic acid (Solvent B).  Flow rate was set to 300 nL/min.  The separation 
gradient was 90 minutes, followed by a 40 minute blank between each sample.  
The sample gradient increased from 2-8% to 5 minutes, 8%-32% to 70 minutes, 
32-50% to 75 minutes, 50%-100% to 80 minutes, 100% to 84 minutes, and then 
to 2% to 90 minutes. Eluting peptides were sprayed into the mass spectrometer 
through a 10 μm emitter tip (New Objective, Woburn, MA). Peptides were 
analyzed at resolution 30,000 within 300–2000 m/z.  The top 8 most abundant 
peptides were individually isolated at isolation width 1.9 Da, and fragmented 
(MS/MS) using collision energy 35.  Fragments were scanned at resolution 7500 
within 350-1800 m/z.  Data-dependent acquisition was used for confident 
identification of as many peptides as possible.  Dynamic exclusion of 30 seconds 
with a repeat count of 1 maximized the number of possible identifications.  MIPS 
(monoisotopic ion precursor selection) was “on.” Lock mass was “on” (silocsane 
371 Da).  Tandem mass spectra were extracted, charge state deconvoluted and 
deisotoped by Proteome Discoverer (v1.3 Thermo Fisher Scientific). All MS/MS 
spectra were analyzed with Mascot (v.2.2 Matrix Science, London, UK) using the 
NCBI 167nr Database, Musculus species with acquired raw MS/MS data, trypsin 
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as the enzyme, 1 missed cleavage allowed, precursor mass tolerance 12 PPM, 
fragment mass tolerance 0.02 Da, and formation of y and b ions. Oxidation of 
methionine and carbamidomethyl of cysteine were specified in Mascot as 
variable modifications. For each sample, Mascot search result *.dat files with and 
without spectra extraction were processed in Scaffold to validate protein and 
peptide identifications.  
In-solution Peptide Isolation for Targeted Proteomics. A proteomic SRM 
assay was developed to quantify the cytochrome Cyp proteins identified in the 
data-dependent mass spectrometry experiment.  Samples for the targeted assay 
were prepared using the filter-aided sample preparation method developed by 
Matthias Mann (Wiśniewski, 2009).  The targeted assay was applied to the 
previously described microsomes, including male and female Balb/c mice in 3 
different age groups, plus pregnant mice and fetuses.  In addition, pooled tissue 
lysates (N=4) of these mice were analyzed, including kidney, lung, intestine, 
heart and brain.  Tissue lysates or microsomes (100 μg) were diluted in 50 μl of 
50 mM ammonium bicarbonate.   Proteins were reduced with NuPAGE Sample 
Reducing Agent (Life Technologies, Carlsbad, CA) for 60 minutes at 60°C. Free 
cysteines were alkylated in 100 mM iodoacetamide at room temperature for 15 
minutes.  Protein was washed with urea (9 M) three times with 300 μl on a 30 
kDa filter (Sigma Aldrich, St. Louis, MO), followed by centrifugation at 14,000 x g 
for 10 minutes.  Urea was removed using 5 washes of 25 mM ammonium 
bicarbonate (300 μl).  Isotope labeled peptides were added (6000 fmol of 1a2 
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peptide and 600 fmol of 2b10, 2d22, 3a11, and 4v2 peptides from a 10:1:1:1:1 
peptide ratio mix). Proteins were digested with 10 μg trypsin for 18 hours.  An 
additional 1 µg fresh trypsin was added after 15 hours.   The peptides were then 
collected by combining flow through and one 200 μl 25mM ammonium 
bicarbonate wash.  Sample was dried under vacuum at 60°C. Each sample was 
resuspended in 40 µl mobile phase A directly before analysis.  Each injection to 
the mass spectrometer contained 5 μg mouse protein (as calculated by the BCA 
assay performed on the microsome or lysate sample) and 30 fmol of 2b10, 2d22, 
3a11, and 4v2 peptides and 300 fmol 1a2 peptide in a volume of 2 μl.   
Targeted Proteomics LC-MS Assay. To write the mass spectrometric method 
and view the targeted method data, the open source program Skyline (MacCoss 
Lab, University of Washington School of Medicine) was employed.  Cyp protein 
sequences obtained from the National Center for Biotechnology Information 
Reference Sequence Database (NCBI RefSeq Database) were imported into 
Skyline in the FASTA format.  Skyline performed an in silico digestion of the 
proteins at lysines and arginines, allowing 0 missed cleavages, +2 and +3 
charges, and length of 5 to 25 residues.  Basic Local Alignment Search Tool 
(NCBI BLAST) was used to determine uniqueness of a peptide to the protein.  
Multiple rounds of transition selection were performed, prioritizing peptides that 
do not contain ragged ends, methionines, cysteines, glutamines and 
asparagines.  One peptide for quantification and one peptide for protein 
confirmation were chosen for the final assay.  The four transitions with the 
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highest signal to noise ratio were retained for the peptide intended for 
quantification; replicate analysis of the sample allowed for confident retention 
time identification. Five representative peptides were chosen for absolute 
quantitation.  All peptides being monitored had either an isotope labeled or 
unlabeled peptide synthesized as a standard.  Heavy labeled peptides (C-
terminal (13C)/(15N) were synthesized by New England Peptide (Gardner, MA), 
and unlabeled peptides were synthesized by Sigma Biosciences (Rockville, MD).   
Mass spectrometry and HPLC parameters for the quantitative proteomics assay 
were determined separately from the peptide and transition selection in Skyline 
(MacLean et al, 2010).  Liquid chromatography was performed by a nanoAcquity 
ultra-performance liquid chromatograph (Waters, Wexford, Ireland) in tandem 
with a triple quadrupole TSQ Vantage mass spectrometer (Thermo Scientific, 
Sunnyvale, CA).  Peptides were separated using a Halo reverse phase C18 
column with 2.7 µm bead diameter and dimensions 2.1 x 100 mm (Mac-Mod 
Analytical, Chadds Ford, PA). Column was heated to 40°C, and samples were 
kept at 6°C.  Flow rate was 100 µl/min. Mobile phase A was 0.1% formic acid in 
water and mobile phase B as 0.1% formic acid in 90% acetonitrile.  The 30 
minute chromatography sequence started at 5% B for 2 minutes, increased to 
60%B to 26 minutes, 98% to 27 minutes, 5% to 28 minutes, and remained at 5% 
to 30 minutes.  Cycle time was 5 seconds, peak widths for Q1 and Q3 were 0.70 
FWHM, and Chromatographic Filter Peak Width was set to 50 seconds.  All ions 
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were monitored in positive mode and analyzed by software Thermo XCalibur 
(version 2.1; Sunnyvale, CA). 
Proteomics Quantitation. The isotope labeled peptide standards were prepared 
in triplicate by spiking commercial Balb/c mouse liver microsomes, following the 
normal sample preparation described above, with dilutions of synthetic isotope 
labeled peptide mix.  Isotope labeled peptide mix was serially diluted from 20 nM 
to 200 μM resulting in a final calibration curve spanning 5 orders of magnitude 
(1.5 fmol, 3 fmol, 15 fmol, 30 fmol, 75 fmol, 150 fmol, 300 fmol, 1.5 pmol, 3 pmol, 
15 pmol).  Quantification was performed using the peptide transition with highest 
signal to noise ratio in the extracted chromatograph of each peptide.  Calibrant 
peak areas were normalized to the 30 fmol peak area and fit to a 1/y2 weighted 
linear regression in GraphPad Prism.  Analyte concentration was calculated from 
the analyte/isotope labeled peptide area under the curve ratio using the linear 
regression equation from the normalized isotope calibrants. The calibration 
curves for the synthetic unlabeled peptides were prepared by serial dilution of the 
equimolar peptide mix from a 500 μM stock in triplicate. Direct injection (2 μl) of 
the dilutions produced calibration points spanning 6 orders of magnitude (1.5 
fmol, 3 fmol, 15 fmol, 30 fmol, 75 fmol, 150 fmol, 300 fmol, 1.5 pmol, and 3 pmol).  
At least 6 of the above dilutions were used for each peptide calibration curve 
according to linear range except the peptides representing proteins 2c37 and 
4a10, which contained 5 points.  Unlabeled peptide standards were averaged 
(n=3) and fit to a 1/y2 weighted linear regression in GraphPad Prism (San Diego, 
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CA).  Relative quantification of peptides was performed using the analyte peptide 
peak area and the regression equation to calculate the approximate 
concentration of peptide in the tissue.   
Microsome Assay. Differences in Cyp activity of the in-house prepared pooled 
microsomes were measured by the microsome activity assay. Total volume per 
reaction was 250 μl, containing 1 mg/ml pooled liver microsomes (20 mg/ml), 
efavirenz (7 μM), potassium phosphate buffer pH 7.4 (0.1 M), and water. The 
reaction was initiated at 37°C in a water bath by the addition of NADPH-
regenerating system (BD Biosciences, San Jose, CA) and incubated 30 minutes 
at 37°C.  The reaction was quenched with the addition of 250 μl 1:1 hexanes: 
ethyl acetate. The samples were then placed on ice 10 minutes followed by 
centrifugation at 10,000 x g and 4°C.  The organic layer was saved, and the 
aqueous protein fraction underwent a second extraction with 250 μl hexanes: 
ethyl acetate.  The organic fractions were combined and dried under vacuum at 
60°C followed by resuspension in 20 μl methanol and 10 μl injection for LC-MS 
analysis.  A fluorinated efavirenz analog was used as an internal standard for 
quantification.  A racemic 6-fluorinated analog of efavirenz was synthesized by 
Dr. David Meyers (Avery et al, 2010; Avery et al, 2013) using modifications of 
previously published meth.  F-EFV was added after the reaction at a final 
concentration of 1 ng/μl.  Signal intensities of 8-hydroxyefavirenz and 5-




Efavirenz Metabolite LC-MS Assay. Determination of metabolite formation was 
performed using a Dionex Ultimate 3000 ultra high-performance liquid 
chromatograph (Thermo Scientific, Sunnyvale, CA) in tandem with a triple 
quadrupole TSQ Vantage mass spectrometer (Thermo Scientific, Sunnyvale, 
CA).  Samples were injected onto an XTerra reverse phase column, with 2.5µm 
C18 beads and 2.1 x 50 mm dimensions (Waters, Milford, MA).  Column and 
samples remained at room temperature during analysis. Sample was injected by 
the Dionex autosampler at a draw speed of 5 µl/s, a dispense speed of 20 µl/s, 
followed by inject wash of 100 µl and loop wash by a factor of 2.  Flow rate was 
0.4 ml/min, with mobile phase A as 0.1% formic acid in water and mobile phase 
B as 0.1% formic acid in acetonitrile.  The column was conditioned at 35% B. 
From 0.2 minutes to 5 minutes, mobile phase B increased linearly to 60%.  
Remaining sample was eluted at 95% B for 0.8 minutes, and the column 
equilibrated at 5% B for 0.2 minutes.  Efavirenz and fluorinated efavirenz were 
monitored using MRMs at m/z of precursor/product ion pairs 313.85/243.98 and 
313.85/243.98, respectively.  Scan width was 0.002, scan time was 0.001, peak 
widths for Q1 and Q3 were 0.70 FWHM, and collision energies were 18 and 20, 
respectively.  Mono- and Di- hydroxylated efavirenz metabolites were monitored 
in product scanning mode.  The expected m/z of the parent ions were 329.821, 
345.789, and 361.765, respectively.  Scan time was 0.1, peak widths for Q1 and 
Q3 were 0.70 FWHM, and collision energies were 14, 17, and 14, respectively.   
36 
 
Product ions were scanned from m/z 50 to 370.  All ions were monitored in 
negative ionization mode.  
Statistical Analysis. Graphs and the two-tailed unpaired t tests were performed 
using GraphPad Prism version 6.02 for Windows (GraphPad Software Inc., San 
Diego, CA).  
 
Results  
Two mass spectrometric methods were employed for identification (global 
approach) and quantification (targeted approach) of murine cytochrome P450s 
(Figure 2-1).   Firstly, for unbiased detection of mouse Cyp expression, we 
performed a global proteomics experiment on liver, kidney, lung, intestine, heart, 
and brain lysates from 9-10 weeks of age male and female mice. Lysates were 
desalted by gel electrophoresis, and the mass region containing Cyps was 
selected for increased coverage of Cyps specifically.  Proteins were digested 
with trypsin in the gel, peptides were separated by nano HPLC and analyzed by 
high resolution Orbitrap MS/MS.  Mascot analysis revealed 22 cytochrome P450 
enzymes in at least one organ of one mouse with 95% confidence containing at 





Figure 2-1. Mass Spectrometry workflows for identification and quantitation 
of murine Cyps.  A proteomics approach was applied to murine Cyp biology. 
 The discovery approach was used to A) compile a list of Cyps expressed in 
mouse liver, kidney, lung, heart, intestine, and brain using a proteomics 
discovery methods, B) develop a SRM assay for the proteins identified, and C) 
use the SRM assay developed to apply a targeted approach to quantitate Cyp 





The proteins identified in female (Figure 2-2A) and male (Figure 2-2B) lysates 
are shown, with the number of confident spectra, “spectral counts,” binned and 
color coded according to detection frequency. Results demonstrated that liver 
readily expresses several known prominent murine Cyps, including Cyps 1a2, 
2b10, 3a11, 2c39 and 2d22 and several Cyps not previously associated with liver 
expression Cyps 2u1, 4a10, 4a12a, 4b1, and 4v2.  The spectral count of proteins 
represents detection of all peptides possible from each protein. Cyps 2b9, 2d9, 
2j5, 3a13, and 4v2 were identified in a single tissue of either male or female 
lysate, reflecting the importance of using both sexes and multiple tissues for 
murine Cyp identification.  Cyps expressed in intestine, heart, and brain were 
undetectable with the protein discovery method, although global proteomics 
experiments are known to be less sensitive than targeted assays.  Five more 
murine Cyp proteins were included in the list for targeted assay development 
because they were identified in mouse microsomes of previous experiments 







Figure 2-2.  Cytochrome P450 expression.  Liver, kidney, lung, intestine, 
heart, and brain of one (A) female and one (B) male mouse of 9-10 weeks 
age were lysed in the presence of protease inhibitors. Cyp enzymes were 
reduced and alkylated, then washed using gel electrophoresis. The mass 
region corresponding to the range of Cyp masses, between 45 kDa and 62 
kDa, was cut and trypsinized.  Peptides were submitted to the Mass 
Spectrometry Core Facility at Johns Hopkins School of Medicine for analysis 
by Orbitrap Velos high resolution mass spectrometer with confidence set at a 
minimum of 2 peptides. Results were searched by mascot and visualized in 
the software Scaffold.  Cytochromes P450 that were not identified in these 
samples are listed because they were identified in female 9 weeks of age, 
fetus, or on the TSQ Vantage mass spectrometer.  All spectra represented in 




The peptide and transition chosen to represent each isozyme for quantitation are 
shown in Table 2-1 and all transitions shown in Table 2-2.  The full assay was 
validated for repeatability in sample preparation, chromatographic retention time, 
and transition linearity for quantitation.  Raw data is visualized as concentric 
chromatograph traces of the peptide transitions, as shown in Figure 2-3. Area 
under the curve of the most abundant transition is used for quantification.  
Absolute quantification using the targeted assay resulted in limits of quantification 
of 30, 0.6, 3, 3, and 3 fmol isotope labeled peptide per µg microsome for Cyps 
1a2, 2b10, 2d22, 3a11, and 4v2, respectively.  Reported abundances are 
calculated based on 5 µg of lysate injected per assay.  The limits of quantification 





Table 2-1. SRM assay design for tryptic peptides and isotope labeled 
peptides.  The cytochrome P450s, protein accession numbers, peptide 
sequences and transitions used for quantitation in the targeted mass 
spectrometric assay are outlined below.  The protein list was generated from a 
global proteomics analysis of protein identified in Balb/c 9-10 weeks of age male 
and female tissues.  All peptides selected are specific to the protein except for the 
Cyp 4a10 peptide, which is identical in Cyp4a32.   
Iso-
zyme Accession no.  Peptide sequence  MRM (parent/transition)  
1a2 NP_034123.1 T254FNDNFVLFLQK265 743.390/747.476 (y6) 
2a12 NP_598418.1 E88ALVDHAEEFSGR100 730.344/1047.449 (y9) 
2b9 NP_034130.1 D263YIDTYLLR271 586.303/780.425 (y6) 
2b10 NP_034129.1 G99TVAVVEPTFK109 574.322/819.461 (y7) 
2c29 NP_031841.3 N49ISQSFTNFSK59 636.815/830.404 (y7) 
2c37 NP_034131.2 Y308AILLLLK315 473.820/712.533 (y6) 
2c39 NP_034133.2 F126TLTTLR132 426.253/603.382 (y5) 
2c50 NP_598905.2 G384TNVITSLSSVLR396 673.886/862.499 (y8) 
2c54 NP_996260.1 E85ALVDHGDVFAGR97 693.344/973.449 (y9) 
2c67 NP_001019890.1 V125FTINTLR132 482.285/503.294 (y4) 
2c70 NP_663474.2 E85ALIDQGDEFSDK97 733.836/1040.417 (y9) 
2d9 NP_034136.2 D408ESVWEKPLR417 629.825/828.473 (y6) 
2d10 NP_034135.2 F369GDIAPLNLPR379 606.840/709.436 (y6) 
2d22 NP_062797.3 T263TWDPTQPPR272 599.796/695.383 (y6) 
2d26 NP_083838.1 G121VILAPYGPEWR132 679.367/454.302 (b5) 
2e1 NP_067257.1 G113IIFNNGPTWK123 623.833/963.468 (y8) 
2f2 NP_031843.2 S48QDLLTSLTK57 553.309/662.408 (y6) 
2j5 NP_034137.1 L50PFVGNFFQIDTK62 763.406/1012.510 (y8) 
2u1 NP_082092.2 E464TFIPFGIGK473 554.805/618.361 (y6) 
3a11 NP_031844.1 L332QDEIDEALPNK343 692.851/358.208 (y3) 
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3a13 NP_031845.1 D244VISFFTTSVER255 700.856/839.426 (y7) 
3a25 NP_062766.2 F447ALISIK453 396.255/573.397 (y5) 
4a10 NP_034141.3 T215YLQAIGDLNNLFHSR230 621.323/887.448 (y7) 
4a12a NP_803125.2 S214YIQAVEDLNDLVFSR229 934.973/1207.595 (y10) 
4b1 NP_031849.1 G125LLVLEGPK133 463.289/642.382 (y6) 
4f13 NP_570952.1 S453PLAFIPFSAGTR465 682.372/735.378 (y7) 




Table 2-2. SRM assay transition list.  The cytochrome P450s and transitions 
monitored for the targeted mass spectrometric assay are outlined below.  The 
three highest intensity transitions per peptide monitored were included in the final 
assay.  The three transitions were used for qualitative assessment of the limit of 
detection, based on signal to noise ratio of the three transitions and consistent 
presence in replicates.  MRMs are represented as parent/fragment in the order of 
highest transition m/z to lowest. Proteins with a star are heavy labeled (13C and 
15N) synthetic peptides included in the assay for quantitation. 
Iso-
zyme MRM1 (transition)  MRM2 (transition) MRM3 (transition) 
1a2 743.390/1008.588 (y8) 743.390/894.545 (y7) 743.390/747.476 (y6) 
 1a2* 747.398/1016.602 (y8) 747.398/902.559 (y7) 747.398/755.491 (y6) 
2a12 730.344/1047.449 (y9) 730.344/932.422 (y8) 730.344/795.363 (y7) 
2b9 586.303/1056.572 (y8) 586.303/893.509 (y7) 586.303/780.425 (y6) 
2b10 574.322/819.461 (y7) 574.322/621.324 (y5) 574.322/500.296 (y4) 
 2b10* 578.329/827.475 (y7) 578.329/629.338 (y5) 578.329/500.296 (y4) 
2c29 636.815/1045.495 (y9) 636.815/830.404 (y7) 636.815/743.372 (y6) 
2c37 473.820/783.57 (y7) 473.820/712.533 (y6) 473.820/599.449 (y5) 
2c39 426.253/704.430 (y6) 426.253/603.382 (y5) 426.253/490.298 (y4) 
2c50 673.886/975.583 (y9) 673.886/862.499 (y8) 673.886/761.452 (y8) 
2c54 693.344/973.449 (y9) 693.344/858.422 (y8) 693.344/721.363 (y7) 
2c67 482.285/616.378 (y5) 482.285/503.294 (y4) 482.285/247.144 (b2) 
2c70 733.836/1153.501 (y10) 733.836/1040.417 (y9) 733.836/797.331 (y7) 
2d9 629.825/828.473 (y6) 629.825/642.393 (y5) 629.825/385.256  (y3) 
2d10 606.840/780.473 (y7) 606.840/709.436 (y6) 606.840/504.245 (b5) 
2d22 599.796/695.383 (y6) 599.796/810.410 (y7) 599.796/369.224 (y3) 
 2d22* 604.800/705.392 (y6) 604.800/820.419 (y7) 604.800/379.233 (y3) 
2d26 679.367/975.468 (y8) 679.367/904.431 (y7) 679.367/454.302 (b5) 
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2e1 623.833/963.468 (y8) 623.833/816.400 (y7) 623.833/702.357 (y6) 
2f2 553.309/890.519 (y8) 553.309/775.492 (y7) 553.309/662.408 (y6) 
2j5 763.406/1069.531 (y9) 763.406/1012.510 (y8) 763.406/898.467 (y7) 
2u1 554.805/878.513 (y8) 554.805/731.445 (y7) 554.805/618.361 (y6) 
3a11 692.851/1143.553 (y10) 692.851/786.399 (y7) 692.851/358.208 (y3) 
 3a11* 696.858/1151.567 (y10) 696.858/794.413 (y7) 696.858/366.223 (y3) 
3a13 700.856/1073.526 (y9) 700.856/986.494 (y8) 700.856/839.426 (y7) 
3a25 396.255/644.434 (y6) 396.255/573.397 (y5) 396.255/460.313 (y4) 
4a10 621.323/862.431 (b8) 621.323/1000.532 (y8) 621.323/887.448 (y7) 
4a12a 934.973/1207.595 (y10) 934.973/1078.553 (y9) 934.973/963.526 (y8) 
4b1 463.289/755.466 (y7) 463.289/642.382 (y6) 463.289/543.314 (y5) 
4f13 682.372/995.531 (y9) 682.372/848.462 (y8) 682.372/735.378 (y7) 
4v2 566.829/886.515(y8) 566.829/702.430 (y6) 566.829/603.361 (y5) 







Figure 2-3. SRM chromatograph.  The chromatograph represents the 2b10 
peptide ATLDPSVPR eluting from a C18 column between 11.0 and 11.5 
minutes.  After the peptide m/z is isolated, it undergoes fragmentation, and a 
single fragment is isolated and detected.  The m/z of the fragment ions are 
indicated by colored traces in the chromagraph. Intensity represents the 




The resulting targeted quantitative mass spectrometry method was applied to 
liver microsomes from 3-4 week, 9-10 week, and 8-10 months of age male and 
female mice (Figure 2-4A).  In addition, microsomes from 10-12 week old 
pregnant mice and mixed sex fetuses were screened (Figure 2-4A).  Brain 
lysates from all mice were analyzed (Figure 2-4D).  Kidney (Figure 2-4B), lung 
(Figure 2-4C), intestine (Figure 2-4E), and heart (Figure 2-4F) lysates from the 
male and female 3-4 week, 9-10 week, and 8-10 month and 10-12 weeks of age 























Figure 2-4.  Cytochrome P450 quantitation in liver microsomes and tissue lysates comparing age, sex, 
and pregnancy status.  Liver microsomes (A) and (B) kidney, (C) lung, (D) brain, (E) intestine, and (F) heart 
were prepared from Balb/c pregnant mice, fetuses, and male and female 3-4 week, 9-10 week, and 8-10 
months of age mice.  Average area under the curve for the three replicates is indicated by color. Cyp enzymes 
were reduced and alkylated, washed with 9M urea on a 30 kDa filter, and trypsinized in a 25mM ammonium 
bicarbonate buffer.  Proteins were analyzed by the targeted SRM assay using the TSQ triple quadrupole mass 
spectrometer.  Absolute quantitation was performed on 1a2, 2d22, 3a11, 2b10, and 4v2, indicated by a star in 




All 27 proteins included in the targeted screen were identified in liver microsome 
samples (Figure 2-4A).  Cyps 4b1, 3a25, 4a12a, and 2c29 were expressed most 
frequently across all organs.  The most abundant proteins were Cyps 2c29, 2d26, 
and 2d10.  Cyp 1a2 and 4a12a appeared to be less abundant in microsomes from 
female mice, and Cyp2e1 appeared to be less abundant in pregnant mice.  For 
most Cyps abundance in the pregnant liver was comparable or slightly less than 
the age matched female mouse, with the exception of Cyp2b9, with higher 
expression in the pregnant mouse. Cyp2b9 also showed higher expression in 3-4 
weeks of age mice in comparison to mice of other ages.  Cyps 4a10 and 4f13 
were detected in high abundance in 3-4 weeks of age female mouse microsomes, 
while abundance was below the limit of quantitation at all other ages. Fetal liver 
expressed Cyps 2b9, 2c37, 2d9, 2d10, and 2d26.  
Cyp 2b9 was detected in the highest abundance in brain tissue (Figure 2-4D). 
Similar to trends in liver microsomes, cyp2b9 was found in higher abundance in 
the 3-4 weeks of age male and female mouse brain lysates compared to adult 
levels.  Pregnant mice Cyp2b9 brain expression was comparable to the other 
adults.  Cyps 2b9, 3a25, and 4a12a were detected in fetal brain lysate. Cyp2c29 
was confidently detected in the 8-10 months female brain lysate.  
The targeted proteomics assay identified 10 of the 27 proteins in kidney lysates 
(Figure 2-4B). Cyps 4a12a, 2b9, and 4a10 demonstrated the highest expression.  
Kidney was the only extrahepatic organ expressing detectable levels of 2e1.  
Male-specific 2e1, 4b1 and 2b9 expression in kidney was identified at all three 
ages.  Cyp2e1 was detected in high abundance in all male kidney lysates, but 
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was not detected in any of the 4 female kidney lysates.  Male Cyp4b1 expression 
was consistently ten-fold higher than female expression at all ages including 
pregnant mice.  Cyp2b9 was detected in male kidney lysates of all ages but only 
one of the four female kidney lysates. Conversely, Cyp3a25 was only detected in 
adult female kidney lysates.  The largest number of Cyps exhibiting sex-specific 
trends was found in the kidney. 
The number of Cyps identified in lung tissue was second only to liver expression: 
15 of the 27 proteins screened were detected in lung tissue (Figure 2-4C).  Cyps 
4a12a, 2f2, 2b9, and 2b10 were amongst the most highly expressed Cyps. In 
contrast to the kidney, no sex-, age-, or pregnancy-specific trends were identified 
in lung tissue.  In comparison to the other extrahepatic organs it appears that 
2c67 and 4v2 were uniquely expressed in lung. 
Proteins detected in the highest number of intestine lysates were Cyps 2c29, 
4a12a, and 3a25 (Figure 2-4E).  Cyps 3a13, 2j5, 2c37, 4b1 and 4a10 were also 
detected. Cyps 4a12a and 4b1 were found in pregnant mice slightly higher than 
age-matched female lysates.  
Cyp2c70 and 2j5 were the most frequently identified proteins in heart lysates 
(Figure 2-4F).  These proteins were also expressed in highest abundance in the 
heart in comparison to other extrahepatic organs.  Cyps 4a12a, 2f2, 3a25, and 
4b1 were also detected. No sex specific, age specific, or pregnancy specific 
trends were identified in heart. 
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Activity assays using mouse liver microsomes and the drug efavirenz were 
performed to demonstrate differences in efavirenz metabolism between sex, age, 
and pregnancy status.  First, we characterized efavirenz metabolism in mice.  8-
hydroxyefavirenz (8-OHEFV), the prominent known metabolite formed in humans, 
was identified by matched retention time and matched spectrum of the 8-OHEFV 
standard (data not shown).  A second species did not match the other known 
efavirenz metabolite, 7-hydroxyefavirenz, either in retention time or spectrum.  We 
propose the identity of the novel compound is 5-hydroxyefavirenz (5-OHEFV).  
Figure 2-5 shows the MS2 spectrum and proposed fragment structures for the 
novel metabolite in the bottom panel.  Fragments 210 and 246 match peaks in the 
8-OHEFV spectrum.  The structures for these fragments were previously 
published.  Unpublished structures are proposed for the peak at 197 and base 
peak at 225, corresponding to fragmentation at various points in the carbon 
chain.  In addition, we reasoned that if the aromatic ring can be hydroxylated in 
two locations (positions 7 and 8), the one position remaining on the ring (position 
5) might similarly be available for hydroxylation. No significant formation of 





Figure 2-5. Fragmentation structure of 5-hydroxyefavirenz.  The MS/MS spectrum of the peak eluting at 2.8 
minutes is shown.  The spectrum reflects a metabolite produced from a reaction with commercial Balb/c liver 
microsome enzymes (n=500).  Proposed fragment structures of 5-OHEFV are indicated for all major peaks with 
arrows. 
1 
To determine the effect of age, sex, and pregnancy status on the metabolism of 
EFV to 8-OHEFV and 5-OHEFV, we compared the in vitro formation of 
metabolites by microsomes between groups.  Areas under the chromatographic 
peaks (Figure 2-6A) were normalized to the F-EFV internal standard. We 
performed two-tailed unpaired t tests in GraphPad Prism; this revealed that 8OH-
EFV (Figure. 2-6B) and 5-OHEFV (Figure. 2-6C) formation was reduced in 3-4 
week old  female microsomes compared to 9-10 week old female microsomes 
(p=0.00353 and p=0.0392, respectively), but not in male microsomes of similar 
ages.  Similarly, 8-OHEFV (Figure. 2-6B) and 5-OHEFV (Figure. 2-6C) were 
formed less by 3-4 week-old female microsomes in comparison to 3 week-old 
male microsomes (p=0.0359 and p=0.0102, respectively), whereas there were no 
differences comparing young and older adult male and females microsome-
generated metabolites.  Microsomes from pregnant mice (10-12 weeks of age) 
demonstrated significantly higher 8-OHEFV  (Figure. 2-6B) production in 
comparison to 9-10 week old females (p=0.0153), whereas 5-OHEFV  (Figure. 2-
6C) was significantly lower in pregnant mice microsome reactions in comparison 
to 9 week-old female microsomes (p=0.0493).  Fetal microsomes demonstrated 
no activity against EFV (data not shown).  These results suggest that metabolism 







Figure 2-6. Efavirenz monohydroxylated metabolite chromatograph and 
normalized peak areas comparing age, sex, and pregnancy status.  A 
chromatograph of monohydroxylated efavirenz metabolites eluting from a C18 
column, selecting for MRM parent/transition pair 329/117 is shown in (A).  
Metabolites were formed by a reaction with commercial Balb/c liver microsome 
enzymes (n=500).  Differences in the formation of 8-hydroxyefavirenz (B) and 5-
hydroxyefavirenz (C) are shown comparing age, sex and pregnancy status.  
Pooled microsomes (n=4) were prepared by liver homogenization and 
ultracentrifugation.  Efavirenz was incubated with microsomes and NADPH for 30 
minutes at 1 mg/ml.  Metabolites were extracted using organic, and fluorinated 
efavirenz was used as internal standard for sample injection.  Peak signal was 








We have demonstrated the relationship between murine protein expression, and 
Cyp activity. We present the Cyp expression profile for mice of 8 metabolically 
relevant groups and 6 organ types, including 6 murine proteins never previously 
identified at the protein level. This is the first proteomic analysis of natural 
variation in cytochrome P450 biology.  
Using global proteomic mass spectrometry, we identified 27 murine Cyps.  
Previous proteomic studies on murine Cyps identified a comparable number of 
proteins, although the isozymes identified differed between studies and mouse 
model systems (Flint et al, 2010; Sutton et al, 2010; Wright & Cravatt, 2007).  
Intensity of Cyp detection in liver microsomes is not indicative of expression in 
comparison to organ lysates due to the enrichment for ER membrane proteins.  
Comparison of tissue lysates between the two mass spectrometry methods 
revealed Cyps identified by the targeted method exceeded that of the global 
method by 4 in kidney, 11 in lung, 8 in intestine, 6 in heart and 4 in brain. Peptide 
detection depends on the complexity of the sample, the amount of protein 
analyzed, and the type of mass spectrometer among other factors.  Absence of 
peptide detection may indicate either no protein, or levels below the limit of 
detection. The Cyps we identified include the murine isozymes structurally 
homologous to the main drug-metabolizing enzymes in human liver.  These 
include 1a2, 2b9, 2c39, 3a11, and 2d9, which are structurally homologous to 
1A2, 2B6, 2C19, 3A4, 2D6, and 3A4 respectively (Pham et al, 2011).  
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Next, we quantified 27 cytochrome P450s across 44 samples, describing protein 
distribution across tissue type, age, sex, and pregnancy status. Cyps 4b1, 3a25, 
4a12a, and 2c29 were the most consistently expressed between mouse organs, 
with detectable amounts of protein identified in more than 5 of the 6 tissues 
tested. Results shown here demonstrate Cyp4b1 in all tissues, especially kidney 
and lung of ages.  In particular Cyp4b1 expression was increased in adult male 
kidney, consistent with reports of dimorphic expression.  Cyp1a2 expression 
appeared to be sexually dimorphic at all ages tested.  Although this trend has not 
been substantiated by proteomics literature, male and female human 
hepatocytes have shown differences in CYP1A2 in response to inducers (Dhir et 
al, 2006).  Cyp3a25 is not yet well characterized, mRNA has been shown to be 
expressed most prominently in liver and intestines similar to our proteomics 
results (Renaud et al, 2011).  Cyp4a12a was well characterized by Muller et al 
2007.  They found that 4a12a contributed to eicosanoid metabolism more than 
the other 4a isozymes tested.  Lower female Cyp4a12a mRNA and protein 
expression was found in comparison to males, which was an exclusively hepatic 
trend (Muller et al, 2007).  Similar to the results presented here, Cyp2c29 mRNA 
is mainly expressed in liver and lung, but also in many other organs (Choudhary 
et al, 2003).  Cyp2c29 detoxifies alpha- and beta-unsaturated aldehydes, found 
endogenously, in food, and in the environment, which can otherwise react with 
genomic material (Amunom et al, 2011).  Most of the extrahepatic cytochromes 
P450 identified in this study demonstrate expression patterns consistent with the 
literatureEight Cyps were identified only in liver microsomes. Cyps 2c39 and 
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2c54 confirm previously reported mRNA expression hepatic profiles (Luo et al, 
1998; Wang et al, 2004), whereas others have been reported in other tissues 
(Bieche et al, 2007; Renaud et al, 2011; Stiborova et al, 2013; Wang et al, 2004). 
The liver is the primary site for drug detoxification, therefore, some liver-specific 
expression was expected.  Finally, the uncharacterized Cyp4f13 also 
demonstrated exclusively hepatic expression.  Little is known about murine 
Cyp4f13, but the 4F subfamily of human and rats is involved in inflammation and 
drug metabolism and was identified by PCR to be expressed in kidney, lung and 
brain as well as liver (Kalsotra & Strobel, 2006).     
Cyp2b9 is the most intensely expressed Cyp, reaching its highest levels in brain 
tissue.  The enzyme functions in anti-carcinogenic activity (Pham et al, 2011) and 
steroid synthesis.  The proteomics data presented here identified Cyp2b9 as 
expressed most highly in the brain compared to other Cyps, and no trends 
toward sexual dimorphism.  Cyp2b9 protein was identified in fetal liver and brain 
samples in this study, but the mRNA primers for Cyp2b9 were not included in 
previous fetal hepatic mRNA screens (Choudhary et al, 2003; Choudhary et al, 
2005).  This result will require more investigation, although it could lead to an 
interesting difference between mRNA and protein abundances.  In contrast to 
extrahepatic proteomic results presented here, Cyp2b9 mRNA expression was 
not detected in kidney, lung, intestine, heart or brain and was found in 
significantly higher abundance in female liver (Hernandez et al, 2006; Renaud et 
al, 2011; Xie et al, 2013).  The detoxification roles of these enzymes might 
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explain their essential function, which requires body-wide expression. The 
cumulative extra-hepatic activity of these enzymes might contribute significantly 
to the total metabolism of an organism, which should be considered in 
experiments such as liver microsome activity assays. 
Cyp4a10 is involved in salt-elimination from the body (Nakagawa et al, 2006). 
Because of this role, expression of Cyp4a10 was expected in the kidney, and, 
while it was not the most abundant Cyp, among all the extrahepatic organs 
where it was it expressed, kidney was the most abundant.  No sexually dimorphic 
trends were observed in hypertension of the knockout mice (Nakagawa et al, 
2006) in contrast with the mild trend for higher protein expression in 3-4 week 
and 9-10 week old female Cyp4a10 expression in kidney.  Other Cyps expressed 
in the kidney also seemed to demonstrate sexual dimorphism in protein 
expression, including Cyps 2d26, 2b9, and 2e1. Cyp2d26 was highly expressed 
in all ages of female kidney lysates, without detection of the protein in either adult 
male tissue. Of these Cyps, no sexual dimorphism was detected in the 
corresponding liver microsomes.  The trends for sexual dimorphism in adult 
kidney but not in liver are confirmed by mRNA expression (Dekant et al, 1995; 
Renaud et al, 2011). Conversely, it is known that mouse Cyp2e1 mRNA is higher 
expression in male tissues (Penaloza et al, 2013), confirming our finding of 
higher Cyp2e1 in kidney of all ages in comparison to female tissue lysates.  
Transgenic studies used male mice exclusively to investigate the biological 
mechanism for 2E1 in alcohol induced liver damage and high-fat mediated liver 
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damage (Abdelmegeed et al, 2012; Morgan et al, 2002). Results presented 
demonstrate the complexity of expression patterns, both hepatically and 
extrahepatically. 
Cyp protein expression in lung also reflects expression patterns with human 
enzymes.  In particular, Bieche et al. identified predominant expression of human 
CYP2F1 expression in lung in comparison to other extrahepatic tissues (Bieche 
et al, 2007).  Similarly, Cyp2f2 was in the top 3 most abundant Cyps expressed 
in lung, and Renaud et al. identified comparable levels of Cyp2f2 expressed in 
lung in comparison to liver (Renaud et al, 2011). Cyps 2b9 and 4a12a were 
expressed equally high as Cyp2f2, although mRNA of Cyp 2b9 and 4a12a were 
not identified in lung (Renaud et al, 2011).  Expression of other Cyps expressed 
in lung such as Cyps 2b10 and 2c70 were shown to be expressed in higher 
abundance in liver (Renaud et al, 2011) and we see evidence of these in some 
samples. Drug metabolizing enzymes in lung are particularly important for 
environmental toxins and drugs delivered by inhalation.  Parkinson et al. are 
investigating bioactivation of a pulmonary toxin by Cyp4b1 using Cyp4b1-null 
mice (Parkinson et al, 2013).  Murine models for drug metabolism inform 
researchers about the function and downstream pathways of a protein which 
could be complemented by mass spectrometric proteomic profiling to maximize 
the amount of information gained from the expensive transgenic experiments.   
Intestine is often the first site of metabolism for oral medications, therefore it is 
one of the primary extrahepatic organs for study of xenobiotic metabolism.  In 
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this study, the 3a and 2c subfamilies were identified in intestine, which are 
homologous to CYP3A and 2C subfamilies detected by immunoblot in human 
intestine (Ding & Kaminsky, 2003).  The 4a, 4b, and 2j subfamilies were also 
identified in mouse intestine, which has not previously been shown in human or 
mouse intestine (Zhang et al, 2003).  
Results demonstrate strong similarities between mouse and human cytochrome 
P450 subfamilies expressed in heart.  Cyp2j5 was detected in mouse liver 
microsomes and mouse heart lysates abundantly in all mouse ages.  Human 
CYP2J2 is well characterized in its localization to the heart (Bieche et al, 2007) 
as well as its xenobiotic and pathogenic role in heart disease (Xu et al, 2013).  
Interestingly, human subfamily CYP2C is known to contribute to ischemic heart 
disease, and while the mRNA has been shown to be not particularly abundant in 
heart (Renaud et al, 2011), the proteomic results presented in our work suggest 
strong expression of a murine Cyp2c family member, Cyp2c70, at all ages. 
Knowledge of Cyp tissue distribution could be used to predict toxicity in a 
particular organ if it is a site for formation of a toxic metabolite.  Similarly, 
knowledge of fetal Cyp expression can inform researchers about the mechanism 
of detoxification or potential formation of a toxic metabolite in neonates.  Cyps 
2b9, 3a25, and 4a12a were detected in fetal brain, which could have implications 
for local drug metabolism and potentially neuroprotection or toxicity which could 
affect neurodevelopment.  The fetal liver expression data presented here, 
including Cyps 2d26, 2d10, 2b9, 2c37, and 2d9 represent a mutually exclusive 
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set of proteins in comparison to previous reports (Choudhary et al, 2003). 
Differences between these data and other published studies may be due to a 
number of differences in the experimental design, including the limit of detection 
of the peptides chosen to represent each murine Cyp in the targeted assay, but 
also due to failure in the assumption that mRNA expression correlates directly 
with protein expression.   
Pregnancy in mice is known to induce or downregulate several Cyps (Koh et al, 
2011).  Our proteomics data demonstrates less expression of Cyp2e1 than other 
adult mice, a result contradictory to the work by Koh et al.  Koh et al. did not test 
for expression of Cyp2b9, which was the only Cyp with increased expression in 
the data presented here.   
Mouse Cyp activity against the HIV-therapeutic drug efavirenz revealed 
significant differences between mice of varying age, sex, and pregnancy status.  
Interestingly, the microsomes made from pregnant mouse livers formed more    
8-OHEFV than age matched female mice.  It has been shown that pregnant 
women taking efavirenz demonstrate increased metabolism of efavirenz in 
comparison to after birth (Cressey et al, 2012).  It is interesting to note that 8-
OHEFV and 5-OHEFV were significantly increased and decreased, respectively, 
indicating metabolism by multiple enzymes.  In humans, multiple enzymes 
contribute to the metabolism of EFV, but CYP2B6 is known to contribute the 
most to the primary metabolite, 8-OHEFV (Ward et al, 2003).  Cyp2b6 in humans 
increases from 9 days old to 28 years old (Tateishi et al, 1997).  Cyp2b6 
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differences in age were significant between female mice of 3-4 weeks of age and 
the 9-10 weeks and 8-10 month old adults.  Male mice did not exhibit a similar 
difference in activity against EFV with age, resulting in significant differences 
between male and female mice at the youngest age. Functional homology of 
Cyp2B6 has not been characterized for the mouse 2b enzymes.  Proteomic 
profiles in this study demonstrate expression of 2b10 in liver microsomes and 
lung, without any striking trends in age-sex-or pregnancy related biology.  
Cyp2b9 is also homologous to CYP2B6, and does demonstrate some age- and 
pregnancy-related trends, although expression patterns do not correlate with 
activity patterns.  Cyp2b9 was expressed in fetal liver microsomes, but no 
metabolite formation was detected in activity assays.  The metabolism of EFV is 
known to be very complex in humans, and is likely to be similarly complex in 
mice, in which case expression patterns of a single enzyme may not be indicative 
of metabolite production.  Further, establishing a causal relationship between 
murine Cyps and EFV metabolite formation would greatly advance an 
understanding of Cyp mechanistic biology and work towards a predictive model 
of drug metabolism. 
Using targeted proteomics and activity assays, we have demonstrated a new 
experimental model for a more integrated approach to molecular pharmacology.  
These experiments are the first to describe protein expression in multiple tissues 
of male and female mice of multiple ages.  Characterization of a mouse model for 
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Histone Post-translational Identification and 





The current approaches used in histone PTM analysis have not been able to 
elucidate site specific identification and quantification in a robust and accessible 
method.  Bottom up mass spectrometry is ineffective in its application towards 
histones because histones have an abundance of lysine and arginine residues so 
that tryptic digestion yields many small peptides (2-4 residues).  Small peptides 
are not easily observed and comprise too few and repetitive sequences that 
make it difficult to establish the location of the modification.  Moreover, the 
principal sites for modification by acetylation, methylation, ubiquitylation, etc. are 
the lysine residues.  When modified these sites generally become “missed 
cleavages” (Garcia et al, 2007b), producing different peptide segments for the 
modified and unmodified forms that are then difficult to compare quantitatively. 
Smaller fragments are also less likely to encompass multiple modification sites, 
and therefore do not provide quantification for combinatorial isoforms. 
The top down approach addresses the peptide size and missed cleavage 
challenges in analyzing histones, but intact histone isoforms are relatively  
resistant to reverse-phase chromatographic separation (Siuti & Kelleher, 2007), 
and the targeting of individual isoforms for data-dependant MS/MS analysis 
becomes exceedingly difficult as multiple precursor ion species with similar 
retention times can result in missing the lower abundance isoforms. Hydrophilic 
interaction chromatography enhances histone application of the top down 
approach (Garcia et al, 2007c) and “middle-down” mass spectrometric analysis 
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using end protease Glu-C digestion has enabled focusing on the tail regions 
where the bulk of the modifications are found (Wang et al, 1999; Young et al, 
2009). Both these methods have been successful, although they are 
cumbersome and often not site-specific. 
The lysine deuteroacetylation technique is particularly advantageous for peptides 
containing multiple lysines because this approach can quantitate the numbers of 
lysines acetylated, distinguishing and quantifying the positional isomeric forms. 
When additional modifications, such as methylation, are also present in the same 
peptide, this approach can be used to quantitatively compare those isoforms 
differing in acetylation but having a common methylation, or other modification, 
site. The deuteroacetyl label eliminates several “biases” common in quantitation 
methods, since enzymatic digestion, chromatographic separation, and ionization 
efficiency (in the mass spectrometer) are effectively normalized for all analyzed 
samples. In our laboratory we have used deuteroacetylation with MALDI tandem 
time-of-flight mass spectrometry previously to determined the percent acetylation 
at K56 on histone H354-63 (FQK56STELLIR) in yeast deficient in sirtuins Hst3 and 
Hst4p (Celic et al, 2006) and identified the major isoforms spanning residues K5, 
K8, K12, and K16 in yeast histone H4 (Cotter et al, 2007). 
In this context, we have continued to develop a bottom up approach that exploits 
and extends the advantages of prior lysine deuteroacetylation using high 
performance mass spectrometry and the application of the approach to other 
modifications.  Specifically, both MALDI TOF and high resolution 
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nanospray/Orbitrap mass spectrometry are used here to characterize the 
positional microheterogeneity of the histone H4 tail region acetylation isoforms in 
HeLa cells and to observe the specific changes to the H4 tail region for cells 
treated with trichostatin A  and nicotinamide, two broad spectrum inhibitors of 
histone deacetylases.  This model system is used to describe the approach 
developed to quantify acetylations. In addition, deuteroacetylation enables the 
observation of methylated (lysine and arginine) species in the context of larger 
peptides that may also be acetylated.  In several examples reported here it is 
shown that monomethylated lysines are derivatized by deuteroacetylation, while 
dimethylated and trimethylated lysines are not.  While the ability to distinguish 
isobars with the same nominal mass is accomplished relatively quantitatively for 
methylated as well as acetylated species using this approach, the additional 
advantages of high mass resolution and accuracy to distinguish acetyl and 
trimethyl modifications are also shown. 
Methods 
Preparation of yeast histones.  Yeast cells containing the appropriate plasmids 
were grown as reported previously (Celic et al, 2006).  Briefly, yeast cells were 
grown at 30oC in YPD medium and arrested in G1 phase using 10 µg/ml α-factor for 2-3 
hours.  The cells were harvested directly or released into the cell cycle in fresh YPD 
medium.  Harvested cells were lysed, nuclei extracted, and histone proteins were 
acid precipitated prior to SDS PAGE to resolve individual histones. 
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HeLa cell culture and histone purification.  HeLa cells were cultured in 
Dulbecco’s modified eagle’s medium containing 10% fetal bovine sera (GIBCO; 
Invitrogen, Carlsbad, CA). Cells were plated and grown to 90% confluence. One 
sample was treated with deacetylase inhibitors: 1 µM Trichostatin A (TSA, 
Sigma-Aldrich, St. Louis, MO) and 10 mM nicotinamide (NIA, Sigma-Aldrich, St. 
Louis, MO) for three hours while the other sample was supplemented with an 
equal volume of solvent alone. TSA and NIA were dissolved in DMSO and 
deionized water, respectively. Cells were then harvested, pelleted and 
fractionated to isolate nuclei. Histones were acid extracted as described in the 
method by Wang et al. (Wang et al, 1999) that provides relatively purified 
histones, and resolved by SDS-PAGE (4-12% NuPAGE™ gels; Invitrogen, 
Carlsbad, CA) with purified chicken core histones (Millipore; Billerica, MA) run as 
markers, and the gel was stained with Coomassie Brilliant Blue. 
Deutero (d3)-acetylation, chemical derivatization and digestion. Using 
reagents provided in the Trypsin Profiler IGD Kit for in-gel digestions (Sigma-
Aldrich, St. Louis, MO), CBB-stained HeLa H4 gel bands were excised, cut into 1 
mm pieces and destained for one hour with a 200 mM ammonium bicarbonate 
solution containing 40% acetonitrile. The destained protein bands were resuspended in 
a solution containing 50 μL deuterated (d4) acetic acid and 10 μL deuterated (d6) acetic 
anhydride (deuterated reagents; Sigma-Aldrich, St. Louis, MO). To ensure the 
derivatization reaction went to completion, gel bands were incubated in the 
deuterated reagents for five hours at room temperature. The treated gel slices 
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were then rinsed with distilled water, titrated with 200 mM ammonium 
bicarbonate (Sigma-Aldrich, St. Louis, MO) to pH 8, rinsed with water again to 
remove remaining buffer salts, and dehydrated/dried in a Speed Vac. Proteins 
were digested in-gel with 0.4 µg trypsin (1 mg/ml in 1 mM HCl) in 40 mM 
ammonium bicarbonate containing 9% acetonitrile, incubated overnight at 37°C 
(Jimenez et al, 2001). Resultant peptides were extracted from the gel and 
lyophilized to dryness before mass spectrometric analysis. All samples were 
reconstituted as stock solutions in 5 μL water with 0.1% trifluoroacetic acid (Pierce, 
Rockford, IL). 
MALDI-TOF mass spectrometry. Matrix solution was prepared as 10 mg/mL α-
cyano-4-hydroxycinnamic acid (Sigma Aldrich, St. Louis, MO) dissolved in a 1:1 
solution of acetonitrile:deionized water containing 0.1% trifluoroacetic acid. 
Undissolved matrix particles were removed via centrifugation. Using the dried 
droplet application technique, resultant matrix solution (1 μL) and the 
resuspended histone H3 and H4 peptide mixtures (1 μL) were spotted on the 
stainless steel MALDI target (Cohen & Chait, 1996). To ensure co-crystallization, 
target plates were spotted at room temperature using the sandwich method: 
deposit 1µL of matrix, 1µL of digest and 1µL of matrix, then redissolve in 50% 
acetonitrile containing 0.1% trifluoroacetic acid.  
Deuteroacetylated HeLa histone H4 peptides were analyzed using a Shimadzu 
AXIMA-TOF2 tandem time-of-flight mass spectrometer (Manchester, UK) 
equipped with a 337 nm pulsed nitrogen laser, high energy collision chamber and 
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curved-field reflectron (Cornish & Cotter, 1993; Cotter et al, 2004). The 
acceleration voltage was set at 20 kV. A four point, external calibration was 
applied per sample spot using a peptide mixture containing bradykinin (m/z 
757.40), angiotensin II (m/z 1046.54), P14R (m/z 1533.86), adrenocorticotropic 
hormone fragment 18-39 (m/z 2465.20), and insulin B chain (m/z 3495.65). All 
peptides used in the calibration mixture were from Sigma Aldrich (St. Louis, MO). 
Each mass spectrum acquired consisted of an average of 500 profiles of 10 
shots accumulated per profile.   
Sample preparation for HPLC-ESI-MS/MS Analysis. 4 μL of stock 
deuteroacetylated peptide mixture were diluted 2.5 fold (to a final volume of 10 
μL) and placed in an Agilent 1200 autosampler (Agilent, Santa Clara, CA). 5 µL 
of each 10 μL sample were loaded by the autosampler through a trapping column 
onto a fused silica PicoFrit (New Objective, Woburn, MA) capillary column, 75 µm 
inner diameter (i.d.) x120 mm long column packed in-house with 5 µm, 300 Å 
BioBasic C18 (Thermo Electron, Bremen, Germany) stationary phase, at a flow 
rate of 300 µl/min. Peptides were separated on-line via reversed phase nano 
HPLC using the Eksigent Nano 2D HPLC pumping system (Eksigent, Dublin, 
CA). The Eksigent Nano 2D HPLC system was controlled by XCalibur software, 
Version 2.0 (Thermo Electron, San Jose, CA). Separations were performed at 
mobile phase flow rate of 300 nL/min on the binary pump system using 0.1 % 
formic acid in deionized water (Solvent A) and 90% (vol/vol) acetonitrile with 
0.1% (vol/vol) formic acid (Solvent B) using a linear gradient of 20-50% A over 60 
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minutes. The outlet flow of the nano-HPLC interfaced directly with the inlet of an 
LTQ-Orbitrap-XL (Thermo Electron, San Jose, CA) allowing for introduction of 
the analyte into the mass spectrometer. 
Tandem Mass Spectrometric Analysis (LTQ Orbitrap XL). The LTQ-
OrbitrapXL mass spectrometer was operated in data dependent mode. MS 
precursor scan spectra (m/z 300-2000) were acquired in the Orbitrap with mass 
resolution of 60,000; the six most intense ions from each MS scan were 
automatically targeted for fragmentation (MS/MS) in the ion trap. Using nitrogen 
as the collision gas, CID mediated peptide fragmentation in the linear ion trap. 
The LTQ OrbitrapXL was controlled by XCalibur software. For each experiment, 
the source voltage was set at 2.4 V, the capillary voltage at 48 V, and the 
capillary temperature at 200˚C. Sheath and auxiliary gases were not necessary 
because nanoflow parameters were being used. The tube lens voltage was kept 
at 105 V, and the ion gauge pressure was 1.5 x 10-5 Torr. The automatic gain 
control was used at the manufacturers default settings for MS collection in the 
Orbitrap (200,000) and MS/MS collection in the ion trap (10,000). Normalized 
collision energy was established at 35% for MS/MS. The default charge state 
was set at two. The isolation window for precursor ion selection was fixed at two 
Daltons. After an initial MS/MS fragmentation event, ions were excluded from 
additional fragmentation rounds for 30 seconds using dynamic exclusion. The ion 
selection threshold, the minimum signal required to trigger tandem mass 
spectrometry, was set to 500. The activation Q was set at 0.25. 
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Quantitation of peptide isoforms. Determining the relative ration between 
acetyl (d0) and deuteroacetyl (d3) ion pairs gives the relative abundance of the in 
vivo acetylated and unmodified peptide forms. The relative acetylation of each 
peptide was determined by an in-house processing method that compares the 
peak height of acetylated peptides to the total for all observed forms of the 
peptide as measured from the charge-state reduced chromatograph of the 
peptides’ elution peak (generated using Xtract software package within 
XCalibur). Charge state reduction was employed such that the peak intensities 
from all charge states of each species were summed over the elution profile. 
Determining the relative ratio between acetyl (d0) and deuteroacetyl (d3) ion pairs 
gives the relative abundance between in vivo acetylated and unmodified peptide 
forms. To determine the relative abundance of positional isomers, where all 
isomeric forms fragment from the same precursor mass in the same MS/MS 
scan, we compared the peak intensities from selected b and y ion pairs 
distinguishing these isoforms (Garcia et al, 2005). Peak intensities from b and y 
ion pairs were summed together and this value was then divided by the total 
produced between both species. 
Results  
Acetyl Quantitation.  Figure 3-1 shows the MALDI time-of-flight mass spectrum 
of the tryptic digest of deuteroacetylated histone H3 from the hst3–H184A yeast 
mutant, a deletion mutant of the Sirtuin Hst3.  The peptide FQKSTELLIR 
encompasses the K56 residue, an acetylation site just inside the histone core 
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region.  In the expanded mass spectrum (Figure 3-1, inset) the acetylated 
FQKAcSTELLIR form is observed at m/z 1276.94 along with its molecular ion 
distribution resulting from naturally occurring isotopes.  Without derivatization, the 
unacetylated analog could not be observed, as K56 would be a tryptic cleavage 
site. With derivatization, the unacetylated analog is also observed as the 
deuteroacetylated peptide FQKdAcSTELLIR three mass units higher at m/z 
1279.95.  Quantitative assessment of the degree of acetylation at this site is then 
based upon the fact that both species are chemically equivalent and that the 
ionization efficiencies are also equivalent.  In this case 43% acetylation is 
determined after correction for the contribution of the 3rd isotope peak in the 
isotopic distribution of the naturally acetylated species to the peak intensity of the 
monoisotopic peak of the deuteroacetylated species. To determine the 
distribution in acetylation, the isotopic distributions of the endogenous and 
deuteroacetylated H4 peptides were simulated based on calculations using MS-
isotope (Protein Prospector Software), available online at 
http://prospector.ucsf.edu/. For this mass and elemental composition the 3rd 
isotopic peak in the naturally acetylated peptide will have an area of 8.60% of 






Figure 3-1. MALDI TOF mass spectrum of the tryptic digest of 
deuteroacetylated histone H3.  Masses corresponding to the peptides 
expected from several of the known post-translational modifications are 
annotated.  Inset: expansion of the H3 54-63 peptide showing the distribution of 





Figure 3-2:  An overlaid plot of two isotopic distributions.  Note the overlap 
of the 4th isotope peaks of the naturally acetylated peptide with the monoisotopic 
peak of the d3-acetylated peptide.  This overlap accounts for 8.60% of the area 






Acetylated H4 tail peptide GK5GGK8GLGK12GGAK16R.  Figure 3-3 is the 
MALDI TOF mass spectrum of the tryptic digest of deuteroacetylated histone H4 
from HeLa cells, again showing the most prominent expected peptides. Of 
particular interest is the histone H4 tail peptide GKGGKGLGKGGAKR 






Figure 3-3. MALDI TOF mass spectrum of the tryptic digest of purified and 
deuteroacetylated histone H4. Masses corresponding to the peptides expected 





In our laboratory, this same approach was used on multiple species of histones, 
including yeast histones and human peripheral blood mononuclear cells (Figure 
3-4).  We demonstrate using MALDI TOF analysis that deuteroacetylation is 
effective with a variety of histone samples isolated and prepared from multiple 






Figure 3-4. Endogenous acetylation distribution on N-terminal H4 peptide 
GKGGKGLGKGGAKR between species.  Histones were isolated from (a) 
genetically modified his-tagged histone H4 yeast growing in log phase and (b) 
human peripheral blood mononuclear cells.  Yeast histones were collected by 
his-tag purification in the lab of Jef Boeke and peripheral blood mononuclear 
cells were isolated by acid extraction from blood of healthy volunteers in the lab 
of Dr. Craig Hendrix. Spectra are labeled according to non-acetylated (d12) to 




In our laboratory, this same approach was used with both MALDI TOF and ESI 
Orbitrap mass spectrometry to monitor effects of the histone deacetylase enzyme 
inhibitors trichostatin A and nicotinamide on the extent of acetylation and on the 
specific distribution of the positional isomeric forms. The MALDI mass spectra in 
Figure 3-5 was used to determine the number of acetylated lysine residues for 
the peptide GKGGKGLGKGGAKR obtained from HeLa cells treated with 
trichostatin A and nicotinamide (Figure. 3-5a) or control (Figure. 3-5b). Following 
derivatization all lysine residues are either acetylated (+42 Da) or 
deuteroacetylated (+45 Da), so that the lowest mass d0 at m/z 1439.03 in this 
isotopic distribution corresponds to GKGGKGLGKGGAKR that is fully acetylated.  
A single acetylation corresponds to the d9 peak, containing one acetylated lysine 
and three deuteroacetylated lysines. The unacetylated peptide is the d12 peak at 
m/z 1451.09.  All of the peptides are chemically equivalent and the distribution is 
obtained from the peak heights of the d0, d3, d6, d9 and d12 species. Then, when 
calculating the actual abundance of each differently modified peptide, the 
contribution of the 3rd isotope peak of the lighter isoforms to the intensity of the 
monoisotopic peak of the isoform heavier by 3 Da must be subtracted. For 
example, the corrected intensity of the d3 GK5GGK8GLGK12GGAK16R peptide 
species is calculated by subtracting 10.75% of the d0 monoisotopic peak from the 
measured d3 peak intensity (Figure 3-6). Corrected distributions for the 
unacetylated to tetra-acetylated species obtained in the MALDI TOF mass 
spectra are shown in Table 3-1 for both the endogenous and deacetylase 
inhibited HeLa cell samples.  
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Figure 3-5b shows the analogous distribution for the histone tail peptide from 
untreated HeLa cells.  Peptides with four acetylated lysines are not observed, 
and in fact three acetylated lysines are of very low abundance.  Most of the 
peptides are unacetylated or mono-acetylated.  Comparison with Figure 3-5a 
shows the effect of the histone deacetylase enzyme inhibitors in promoting a high 
degree of acetylation.  From Table 3-1, approximately 57% of isomers present in 
the endogenous HeLa H4 tail peptide had no acetylated lysine, i.e. the most 
abundant isoform of this peptide was unmodified.  31% of the peptide had one 
acetylated lysine, and 9% had two acetylated lysine residues. Less than four 









Figure 3-5. MALDI TOF mass spectra of the expansion of 
GKGGKGLGKGGAKR for HeLa cells treated with deacetylase inhibitor and 
control.  The distribution of the non-acetylated (d12) to tetra-acetylated (d0) 
species is shown for (a) histone derived from trichostatin A/nicotinamide 







Figure 3-6.  Calculated Isotope distributions for various isoforms of the 
deuteroacetylated GKGGKGLGKGGAKR.  Histone H4 tail tryptic peptide 
(residues 4-17) S2F shows an overlaid plot of the isotopic distributions of all 
isoforms.  Note the overlap of the 4 isotope peaks with monoisotopic peak of the 
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Table 3-1. Relative abundances of each differentially modified peptide population 
for the model GKGGKGLGKGGAKR peptide. A comparison of isotopically 
corrected data derived from both the LC-ESI MS and MALDI-TOF is shown. 
 No deacetylase inhibitor With deacetylase inhibitors 
Trichostatin and Nicotinamide 
 MALDI TOF ESI Orbitrap MALDI TOF ESI Orbitrap 
No acetylation 57% 63% 10% 8% 
1 acetylation 31% 29% 19% 14% 
2 acetylations 9% 7% 21% 20% 
3 acetylations 3% 1% 22% 26% 






Quantitation of H4 tail peptide isoforms using ESI Orbitrap MS/MS analysis. 
Tryptic digests of the deuteroacetylated histones were analyzed using on-line 
HPLC MS/MS. We confirmed that all 16 of the acetylated/deuteroacetylated 
chemically and chromatographically equivalent species of the tail peptide 
GK5GGK8GLGK12GGAK16R eluted from the column at the same time (Figure 3-
7), including the fully deuteroacetylated (b), singly acetylated (c), doubly 
acetylated (d), triply acetylated (e), and quadruply acetylated (f). While some 
small chromatographic differences were detected for peptides with different 
numbers of in vivo acetylations (note the peak spread in Figure 3-7a), by contrast 
positional isoforms, with the same number of naturally-occurring acetylations 
(and same molecular weights), had identical narrow retention times. Figure 3-8 is 
the ESI Orbitrap mass spectrum of the doubly-charged molecular ions of the tail 
peptides from the (a) untreated and (b) trichostatin A/nicotinamide treated HeLa 
samples.  The extracted (isotopically corrected) relative abundances of the 
unacetylated to tetra-acetylated species are shown in Table 3-1, and are similar 






Figure 3-7. Chromatographic traces for the acetylated/deuteroacetylated 
isoforms of GKGGKGLGKGGAKR. The H4 4-17 peptide 
GKGGKGLGKGGAKR doubly-charged molecular ions elution from a C18 column 
interfaced to a nanospray ionization source were monitored on an LTQ/Orbitrap 





Figure 3-8. ESI Orbitrap mass spectra of GKGGKGLGKGGAKR for HeLa 
cells treated with deacetylase inhibitor and control.  The doubly-charged 
molecular ion regions for the acetylated/deuteroacetylated isoforms of peptide 
GKGGKGLGKGGAKR integrated across the chromatographic retention times are 





Doubly-charged molecular ions of the unacetylated to tetra-acetylated tail 
peptides GK5GGK8GLGK12GGAK16R were each targeted for MS/MS 
fragmentation and the tandem mass spectra from the elution peak were 
summed. Figure 3-9 shows the MS/MS spectrum of the doubly-charged 
molecular ion m/z 719.90, which corresponds to the d0 (fully-acetylated) species 
from the TSA/NIA-treated sample.  There is only one positional isomer with this 
molecular weight giving rise to a single set of b-series and y-series ions. From 
these we selected three b and y fragment ion “pairs” that describe the 
fragmentation between the four lysine residues: 
 
In choosing these ions we selected those that appear with reasonable intensity in 
all of the subsequent spectra of mixed isoforms. The standard deviation between 
selection of b in comparison to y ions according to cleavage at the same bond 





Figure 3-9. ESI Orbitrap MS/MS spectrum of fully acetylated 
GKGGKGLGKGGAKR.  The doubly-charged molecular ion of the fully 
acetylated (d0) isoform of the peptide GKGGKGLGKGGAKR is shown 
highlighting the b-series (b3, b5 and b9) and y-series (y5, y7 and y11) ions used to 





Figure 3-10 shows expansions of the mass regions about the six fragment 
ion masses for the mono-acetylated isomers.  Each of these b and y ions 
appears at two masses according to an acetylated and a deuteroacetylated 
isoform and can be used to describe the relative abundances of the isomeric 
forms. For example: b3 shows the ratio between ions acetylated at K5 and those 
acetylated at any of the other three lysines.  The y11 fragment does the same, 
though the order of mass and acetylation/deuteroacetylation assignment is 
reversed because the N-/C-terminal end of the peptide (b3 or y11) is reversed.  
These two ratios were averaged to produce the entry on Table 3-2 of 7.3% 
acetylation at K5 and 93% acetylation on all other lysines.  The b5 and y7 ratios 
then determine the relative abundances of acetylation at K5 or K8 versus K12 or 
K16.  And the b9 and y5 ratios determine the percentage acetylated at K16.  
Combining these data (Table 3-2), we determined that the composition for the 







Figure 3-10. Expanded MS/MS spectral regions of monoacetylated 
GKGGKGLGKGGAKR.  The mass spectral regions of the b-series (b3, b5 and 
b9) and y-series (y5, y7 and y11) ions used to quantitate the positional isomers of 






Table 3-2. Fractional abundances of fragment ions of mono-acetylated 
GKGGKGLGKGGAKR peptide from histone H4 from HeLa cells.  
Fragment ions acK5 acK8 acK12 acK16 
y5 and b9 0.256 0.744 
y7 and b5 0.127 0.873 
y11 and b3 0.073 0.927 
Untreated HeLa cells 7% 5% 13% 74% 
y5 and b9 0.303 0.697 
y7 and b5 0.146 0.854 
y11 and b3 0.063 0.937 





There are six potential isomeric forms of the diacetylated H4 tail peptide4-17, 
which can be deciphered by computing relative abundances from the fragment 
ions of the MS1 isoform peak.  Although it is statistically not possible to 
distinguish all the diacetylated isomeric species from unique fragment masses, 
we determined that about 6% of untreated diacetylated peptide4-17 was 
acetylated at the K5 and K8 residues, whereas 20% were mixtures of acK5acK12 
and acK5acK16, 34% comprised mixtures of acK8acK12 and acK8acK16, and 40% 
were acK12acK16 (Table 3-3). When the deacetylase inhibitor-treated histone H4 
sample was evaluated, the most dominant diacetylated isomer was the 
acK12acK16 peptide, which constituted 59% of all diacetylated species. Three 
percent of the treated, diacetylated peptide4-17 was acK5acK8, 14% was the 
combination of acK5acK12 and acK5acK16, and 24% was the combination of 
acK8acK12 and acK8acK16.  Results for the tri-acetylated peptide species are 
summarized in Table 3-4. In untreated samples, 23% of the triacetylated 
peptide4-17 was acK5acK8acK12, 10% was acK5acK8acK16, 28% was 
acK5acK12acK16, and acK8acK12acK16 comprised 39%. For the trichostatin 
A/nitotinamide treated samples, 6% of all triacetylated peptide4-17 species were 
acK5acK8 acK12, 11% of the total was acK5acK8acK16, 20% was acK5acK12acK16 







Table 3-3. Fractional abundances of fragment ions of di-acetylated 
GKGGKGLGKGGAKR peptide from histone H4 from HeLa cells. 












y7 and b5 0.056 0.541 0.402 
y11 and b3 0.255 0.745 
Untreated HeLa cells 6% 20% 34% 40% 
y7 and b5 0.032 0.373 0.595 
y11 and b3 0.168 0.832 
TSA-treated HeLa cells 3% 14% 24% 59% 
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Table 3-4. Fractional abundances of fragment ions of tri-acetylated 
GKGGKGLGKGGAKR peptide from histone H4 from HeLa cells. 












b9 and y5 0.231 0.768 
y7 and b5 0.327 0.673 
y11 and b3 0.607 0.392 
Untreated HeLa cells 23% 10% 28% 39% 
b9 and y5 0.064 0.936 
y7 and b5 0.174 0.826 
y11 and b3 0.379 0.621 






Combining the distributions of Tables 3-2, 3-3, and 3-4, we can determine the 
relative abundance for all positional isomers. Thus Table 3-5 displays the relative 
abundance of all 16 acetylated isoforms for the tail peptide. Without deacetylase 
inhibition, the most abundant peptide isoform is unacetylated (63%). The second 
most abundant isoform had a single acetylation at residue K16 (22%). In the 
presence of deacetylase inhibitors, as would be predicted, the most abundant 
peptide is fully acetylated (32%). Compared to untreated controls, no single 
modification profile predominates; however, isoforms that include modifications at 




Table 3-5. Relative abundance of all 16 positional differentially modified 
peptides from HeLa cells comparing presence of deacetylase inhibitors.  HeLa 
cells treated with deacetylase inhibitors TSA and NIA were analyzed for site-
specific modifications on the histone H4 peptide GKGGKGLGKGGAKR. 
Lysine residues in red indicate acetylation. 
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G K G G K G L G K G G A K R 2% 1% 
                
G K G G K G L G K G G A K R 1% 1% 
                
G K G G K G L G K G G A K R 4% 2% 
                
G K G G K G L G K G G A K R 22% 10% 












G K G G K G L G K G G A K R 0.4% 0.6% 
                
G K G G K G L G K G G A K R     
              1% 3% 
G K G G K G L G K G G A K R     
                
G K G G K G L G K G G A K R   
              2% 5% 
G K G G K G L G K G G A K R   
                
G K G G K G L G K G G A K R 3% 12% 












G K G G K G L G K G G A K R 0.20% 2% 
                
G K G G K G L G K G G A K R 0.10% 3% 
                
G K G G K G L G K G G A K R 0.30% 5% 
                
G K G G K G L G K G G A K R 0.40% 16% 
                  




Methylation of the K79 site in histone H3. It is more difficult to design an 
analogous strategy that uses isotopically labeled methylation to elucidate 
methylation sites for two reasons: because lysines may be mono-, di- and tri-
methylated and because methylation can also occur on arginine residues. Figure 
3-11 shows MALDI TOF mass spectra of the yeast histone H3 fragment 
EIAQDFKTDLR corresponding to residues 73-83.  An incomplete tryptic 
digestion of underivatized wild-type histone H3 is shown (Figure. 3-11a), 
revealing peaks corresponding to peptides unmodified, methylated, dimethylated 
and trimethylated (or acetylated which is found at the same m/z) at K79 . Tryptic 
digestion of the deuteroacetylated histone H3 fragment in Figure 3-11b shows 
both the unmethylated and mono-methylated species have been derivatized, 
while the dimethylated and trimethylated (or acetylated) species are not 
derivatized.  Specifically the unmodified peptide seen at m/z 1335.85 in Figure 3-
11a now appears at m/z 1380.97 as the deuteroacetylated species three mass 
units above the trimethylated (or acetylated) species at m/z 1377.82. 
Derivatization of the mono-methyl species is observed in Figure 3-11b at m/z 





Figure 3-11. MALDI TOF mass spectrum of the methylated yeast histone H3 
73-83 peptide EIAQDFKTDLR.  The spectrum shows (a) unmethylated peptides 
and peptides methylated, dimethylated and trimethylated at lysine 79 and (b) 






Electrospray mass spectra were also obtained for a yeast histone H3 sample 
containing unmodified and methylated K79 in part to differentiate trimethylated 
and acetylated species by high mass resolution of the Orbitrap.  MS/MS spectra 
are shown in Figure 3-12, where the high mass accuracy obtainable from the 
Orbitrap mass spectrometer is noted for several of the major fragment ions. A 
deuteroacetylated  tryptic digestion contained methylated/deuteroacetylated (a) 
and deuteroacetylated (b) species.  Interestingly, modification of the basic lysine 
residue in both cases produces fragmentation patterns that are quite equivalent. 
On the chromatographic time frame (Figure 3-13), the retention times are similar, 
though not identical.  Integration of the mass spectra across this range of 





Figure 3-12. ESI Orbitrap MS/MS spectra of methylated EIAQDFKTDLR.  The 
doubly-charged molecular ions of the derivatized peptide EIAQDFKTDLR is 
shown to be (a) methylated at lysine 79 and (b) unmethylated.  The different 
masses of the y7 and y9 ions distinguish the two species.  Mass accuracy is 





Figure 3-13. Methylated and unmethylated histone H3 EIAQDFKTDLR 
peptide HPLC chromatographs.  C18 HPLC single ion chromatographs of 
derivatized (a) unmethylated and (b) methylated EIAQDFKTDLR obtained by 






Figure 3-14. Methylated and unmethylated histone H3 EIAQDFKTDLR 
spectral integration for quantitation.  Elution peaks of methylated and 
unmethylated EIAQDFKTDLR peptide were integrated to generate spectrum 




Methylation of histone H3 peptide KSAPSTGGVKKPHR.  A tryptic fragment at 
m/z 533.6494 corresponds to the expected mass of the triply-charged peptide ion 
from the yeast H327-40 peptide KSAPSTGGVKKPHR carrying a methyl group and 
three deuteroacetylated lysines. The arginine residue and all three lysines are 
potential methylation sites.  The MS/MS spectrum of the triply-charged molecular 
ion is shown in Figure 3-15.  All of the observed b-series and y-series ions 
support methylation at either the K36 or K37 residues.  The fragment ion that 
should distinguish these two possible structures is the singly-charged y4 ion, 
where the major peak at m/z 582.3545 (Figure 3-15 inset) corresponds to 
methylation of the K36 lysine.  The mass accuracy of 0.8 ppm obtainable on the 
Orbitrap mass analyzer is excellent and consistent with the mass accuracy in that 
range for other observed fragment ions.  A smaller peak at m/z 596.3589 may 
correspond to the y4 ion of a structure in which the K37 site is methylated, 
although the low intensity, signal to noise ratio, and low mass accuracy at 20 






Figure 3-15. ESI Orbitrap mass spectrum of the molecular ion of the singly 
methylated and fully deuteroacetylated H3 peptide KSAPSTGGVKKPHR.  
Both the fragmentation pattern and mass accuracy are used to determine the 
location of the methylated lysine.  The major y4 fragment ion at 582.3545 differs 
0.8 ppm from the calculated mass 582.3550 of isoform having methylation at the 
second lysine. A smaller peak at 596.3589 is close to the expected mass for the 






Trimethylation of histone H3 peptide KSAPSTGGVKKPHR. The 
deuteroacetylated histone H327-40 peptide from HeLa cells also reveals a 
trimethylation site.  The MS/MS spectrum of the triply-charged molecular ion 
observed at m/z 527.9819 is shown in Figure 3-16, and shows the same 
characteristic ions corresponding to b2
+1, b3
+1 and y11 to y13.  These fragment 
masses are consistent with a structure having two deuteroacetyled lysine 
residues and a trimethylated lysine residue, and are accurate within 2-3 ppm.  In 
contrast, errors in the mass accuracies when compared with a structure having 
two deuteroacetylated and one acetylated lysine are of the order of 20-30 ppm, 
the approximate mass difference between an acetyl and a trimethyl modification.  
The masses of the b2
+1and b3
+1 ions preclude trimethylation on the K27 residue, 
but no fragment ion was observed that would distinguish between trimethylation 
at the K36 and K37 sites.  Based upon the observation of methylation at K36 in the 







Figure 3-16. High resolution ESI Orbitrap MS/MS spectrum of 
KSAPSTGGVKKPHR peptide distinguishes acetylation from trimethylation.  
The inset table lists the high intensity ions observed for PTM identification, the 
calculated mass from the peptide listed above, and the difference in mass 
between calculated and observed.  Differentiation between acetyl and trimethyl 





There is considerable interest in developing global mass spectrometry 
approaches to assess lysine acetylation, particularly as this type of modification 
now appears to play significant roles in many cellular processes and species.  
We demonstrate our quantification method using bottom up derivatization for 
acetyl-lysine quantification and non-acetylation identification on histones using 
high resolution mass spectrometry. There are sixteen potential positional 
isomeric forms of the acetylated/deuteroacetylated peptide 
GK5GGK8GLGK12GGAK16R, including four mono-, six di- and four tri-acetylated 
species. Quantitation of positional isomers having the same precursor mass 
could not be determined using MALDI tandem analysis.  Time-of-flight 
instruments generally have somewhat limited mass selection capability, so one 
cannot select isotopically pure precursors.  Nonetheless, our preliminary work with 
this instrument indicated that the major monoacetylated species was acetylated at 
K16, while the major diacetylated species was acetylated on K8 and K16 (Cotter et 
al, 2007).  This of course motivated our use of the LTQ/Orbitrap mass spectrometer 
to provide detailed analysis of the positional isomers. 
 The yeast histones analyzed in this study confirm previous results from this lab 
that K16Ac is the major mono-acetylated isoform (Cotter et al, 2007). Our findings 
are also consistent with previous biological studies. Histone H4 K16 acetylation is 
a reversible modification implicated in the widespread process of chromatin 
condensation by recruiting HATs to acetylate K12, K8, and K5. In mammals, K16 
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acetylation also correlates with K20 trimethylation (Sarg et al, 2004). Using an 
antibody approach to study site specific lysine acetylation in yeast histone H4, 
Suka et al. (Suka et al, 2001) found that lysine acetylation in the H4 N-terminal 
peptide4-17 occurs sequentially from the C-terminus to the N-terminus: K16 
acetylation precedes K12Ac, which precedes K8Ac, leading finally to K5Ac. We 
found similar results for H4 tail peptides from TSA/NIA treated HeLa cells: 6% of 
the monoacetylated peptide was acetylated at the K5 residue, 8% at the K8 
residue, 16% at K12, and 70% at K16 (Table 2). 
Identification of the methylated peptide EIAQDFKTDLR in the deuteroacetylated 
sample was made simpler by the predictable trypsin cleavage pattern and the 
known mass shift.  We identified that modification of either lysine residue with a 
methyl group in both cases produces equivalent fragmentation patterns, 
suggesting that their comparable ionization and fragmentation behavior may 
provide an opportunity to make some assessment of the degree of methylation.  
Absolute quantification is not possible due to the retention time and ionization 
differences between species, although our results suggest a possility for 
calculation of relative abundance. 
Other groups such as Zhao et al. (Zhang et al, 2009) have used alternative 
methods to quantitate lysine acetylation. Their approach utilizes anti-acetyl lysine 
antibodies to enrich for endogenously acetylated proteins and stable isotope 
labeling with amino acids in cell culture (SILAC) for quantitation by mass 
spectrometry. The sirtuin proteins have been shown to have deacetylase activity 
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in mitochondria (Schwer et al, 2006).  Another group, Kelleher et al. (Li et al, 
2009), report a method for global histone profiling in response to inhibition or 
knockdown of human deacetylases using a linear ion trap fourier transform mass 
spectrometer. In this approach, histone mixtures are subjected to methionine 
oxidation prior to chromatographic separation to enable resolution of each 
histone type (H1, H2.B, H2A-1, etc.).  The high mass resolution and accuracy of 
the fourier transform mass spectrometer then enable one to determine the 
numbers of acetyl and methyl groups, and the method generally regards these to 
be the most abundant isoforms, e.g. H4+2Me occurs on H4K20, H4+2Me +2Ac 
occurs as H4K202MeK12AcK16Ac, etc.  This approach has the advantage of 
assessing all of the possible modification types, provides some quantitation of 
the overall modifications, but does not use MS/MS to provide details of positional 
isomeric forms.  Alternatively, top down methods using electron capture 
dissociation on the fourier transform instrument  (Siuti & Kelleher, 2007) provide 
structural verification of the major isoforms, but are not necessarily as 
quantitative as isotope based methods. 
Our interest in the bottom up approach and chemical derivatization is based upon 
the possibility for exquisite and facile quantification of acetylation at specific 
residues, which was established in an earlier study by us of the acetylation of the 
K56 site in histone H3 for a series of hst3 and hst4 mutants (Celic et al, 2006).  In 
that study, MALDI mass spectra of protein digests (as shown in Figure 9) were 
obtained for histones derived from wild type, deletion mutants and H184A, 
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N152A and D154A mutants.  Using this quantitative method for cells 
synchronized in G1 phase, we were then able to monitor changes in K56 
acetylation to observe the inactivation of Hst3/Hst4p during passage through S 
Phase in response to NIA. Regulation of histone H3 K56 has been shown to be 
critical in the cell cycle of fungi (Xhemalce et al, 2007) and is regulated by the 
fungal histone acetyltransferase Rtt109 (Tang et al, 2008), a homolog of 
p300/CBP specific for K56.  In addition to the peptide containing K56, expansion of 
the isotopic displays from the MALDI mass spectra enabled quantitation of the 
acetylation of lysine residues in K9STGGK14APR and K18QLASK23AAR in histone 
H3. 
In addition to obtaining quantitative information on acetylation at the positional 
isoform level, the intent is to begin to utilize this bottom up derivatization method 
to provide qualitative and semi-quantitative analyses for other modifications, 
particularly methylation, dimethylation and trimethylation.  Methylation of the K79 
site on histone H3 is of particular importance in cell cycle and replication, and 
Kelleher et al. (Sweet et al, 2010) have recently used a stable isotope strategy 
(SILAC) and mass spectrometry to compare the methylation and dimethylation of 
pre-existing and newly-synthesized histones. While it is clear that the 
deuteroacetylated structures: EIAQDFKMe+dAcTDLR and EIAQDFKdAcTDLR 
encompassing the K79 site are not chemically and chromatographical identical, as 
in the case of stable isotope analogs, their similar responses to ionization and 
mass spectral sensitivity suggest that with the proper peptide analog experiment, 
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analyses intended to observe changes in methylation at this site could be easily 
calibrated for accurate quantitation. 
A bottom up approach using global chemical derivatization of endogenously 
unmodified lysines is an effective alternative to other mass spectrometric histone 
analysis methods in quantification of site-specific histone acetylation.  Finally, this 


















The field of proteomics is expanding rapidly as new proteomic techniques are 
being developed and novel proteomic applications are expanding biological 
research.  The work presented in the first part of the thesis demonstrates the 
application of the established SRM technique to describe natural variation of a 
highly similar protein family in a novel population where other methods of protein 
quantification were impractical.  This research will serve as a resource for many 
researchers interested in the murine Cyp pharmacology.  Furthermore, 
introduction of proteomics as a biological tool for evaluation of global Cyp 
expression differences in the field of Cyp biology expands the field of proteomics 
by the exposure of basic biologists to the powerful proteomic techniques 
available.  The Cyp SRM assay presented in this research could be applied to 
determine the dynamics of Cyp expression in a disease model or induction 
experiment.   
Because few studies aim to make functional correlations with human proteins 
and limited information is available regarding when and where murine proteins 
are expressed, the Cyp expression results presented in this thesis are 
exclusively descriptive.  Murine Cyp activity could be correlated to Cyp protein 
expression by activity assays with pure Cyp isozymes.  This is done using 
recombinant bacteria to purify a single Cyp and incubating each Cyp with 
substrates known to be nearly exclusively metabolized by a particular Cyp and 
other substrates of interest.  Establishing murine Cyps functionally homologous 
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to well-characterized Cyps through metabolism of a common substrate will make 
the proteomics work presented here more accessible to researchers in all basic 
science fields.   
Because the cytochrome P450 family is highly homologous, the choice of 
peptides for protein quantitation was limited for certain isozymes, resulting in 
variability in peak intensity.  Further Cyp proteomics experiments would benefit 
from improving results statistics.  This could be done by establishing individual 
variability by analyzing protein from individuals instead of pooled sample. 
Further, reproducibility of peptides with lower ionization efficiency could be 
enhanced with replicate injections.  All peptides do not ionize equally efficiently, 
and for those that ionize less well, replicates display more variability.  Three 
injection replicates in addition to the three technical replicates performed would 
drastically increase the amount of instrument time and therefore cost of the 
experiment, although they would significantly enhance the statistical power of the 
resulting data. 
The Cyp SRM assay could be applied to humanized or knockout mouse models 
to test the induction of cytochrome P450s with elongated drug usage or in 
determining differences in Cyp expression.  For example, Johnson et al. are 
investigating the role of 4A11 in hypertension using a humanized mouse model 
(Savas et al, 2009).  In addition to characterizing changes in signaling pathways, 
they asked us to employ the cytochrome P450 SRM assay to evaluate if 
118 
 
cytochrome P450 expression is also altered, and therefore, potentially implicated 
in a similar expression pathway as their CYP of interest.   
By continuing to establish more accurate, quicker and easier quantitative 
methods, better tools for the field of mass spectrometry will be available for 
application to new biological questions.  The PTM identification and quantification 
research discussed in Chapter 3 could be further established by validating 
quantification on methylated and acetylated synthetic peptides.  Performing 
analysis on known mixtures of methylated and acetylated peptides would 
determine the precision of the quantitation calculation.  In addition, one challenge 
in the application of the technique using LC-MS was to reduce sample complexity 
and background influence, as the high abundance of unacetylated peptides 
seemed to dominate the data-dependent MS/MS targeting.  Analyzing the 
synthetic modified peptide mix in an E. coli digest would establish the robustness 
of the technique in a large mixture in comparison to traditional data-dependent 
searches.  Furthermore, newer models of Orbitrap mass spectrometers have at 
least double the scanning speed, such that more peptides of interest might be 
targeted for fragmentation.  These experiments could establish the technique as 
a validated system using any instrument or platform and any protein mixture.   
The LTQ Orbitrap XL used for the experiments in Chapter 3 was one of the first 
Orbitrap models in academia, acquired in 2008.  In the last 5 years, Orbitraps 
have become faster and more specialized, including the Velos with a dual-
pressure linear ion trap to more than double the dynamic range at the same 
119 
 
scanning rate, the Elite with a high-field Orbitrap” which quadruples the 
resolution, the Exactive with a streamlined Orbitrap-only detection, and most 
recently the Fusion with a high field Orbitrap and two other detectors for the most 
flexibility in experimental design.  A streamlined instrument for FT-FT detection 
with higher scan rate and higher resolution would be the instrument of choice for 
PTM quantification described here: the Elite, although both the histone PTM 
project and the cytochrome P450 project could have been conducted on the 
Thermo Fusion. 
PTM identification work presented here did not include a practical way to identify 
peptides of unknown sequence that could potentially be modified.  One method 
which I started to pursue at the beginning of my PTM identification work was to 
identify all acetylated peptides in comparison to the deuteroacetylated version of 
that peptide.  It is standard to export a list of peak m/z and peak intensities, so I 
wrote an Excel Macro to eliminate masses with peak intensity below signal to 
noise, identify all peaks with a user-defined mass difference, and report all 
matches and peak intensities in a new excel sheet.  This analysis was versatile, 
as the input mass difference could be either 3, 15, 12 or 27 for acetylation, 
methylation, dimethylation, or trimethylation, respectively.  Although the macro 
identified all shifted peaks, the isotope elimination functions were ineffective at 
reducing false-positives, which made this analysis impractical. Another method to 
manually identify peaks corresponding to deuteroacetylated peptides in an 
unknown protein sample would be to compare mass spectra of a 
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deuteroacetylated sample to an identical but not deuteroacetylated sample would 
reveal one simple and one complex spectrum.  Peaks that were more intense in 
the deuterated sample would indicate a lysine-containing peptides.   After a peak 
has been identified as a K-containing peptide, all peaks of potential modifications 
including the mass shifts listed above can easily be targeted for MS/MS 
identification.  The use of the MALDI-TOF instrument for this analysis instead of 
Orbitrap has the advantage of using approximately 1/20th that of an Orbitrap 
analysis.  In addition, all the information about the sample is contained in one 
spectrum, allowing for facile quantitation or relative abundance.  Although these 
are interesting directions, these method optimizations have utility for a narrow 
subset of biological samples.   
One research area that would benefit the whole field of proteomics would be to 
characterize the chemistry of peptide ionization.  The chemical composition of 
the peptide and the whole protein is not an indicator for its success in mass 
spectrometric analysis, as it is not yet understood what chemistry composition in 
an analyte is best detected in a mass spectrometer (Mirzaei & Regnier, 2006).  
Currently, all peptides in a protein are experimentally evaluated for ionization 
efficiency.  In cases such as the Cyp work presented here, the biological sample 
is also the sample used for method development.  In the case of low abundant 
Cyps such as Cyp2u1, detection was noisy and peptide choice was not 
supported by any scientific findings regarding if it was predicted to be an 
adequate candidate for SRM.  SRM analysis usually requires an expensive 
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synthetic peptide, so selection of a poor SRM candidate peptide can be a costly 
mistake. A prediction tool for SRM peptide selection will be a cost and time-
saving tool for proteomics mass spectrometrists using triple quadrupole 
instruments. 
The field of proteomics mass spectrometry is beginning to include biologists in 
addition to biology-inclined mass spectrometrists and chemists. The hundreds of 
megabytes of data generated per LC-MS analysis are available online by 
journals such as in Nature Methods and by academic groups such as 
PeptideAtlas.  This exponentially growing field currently defines global protein 
identification and quantification, and the network of information it produces will 
provide a rich resource of global protein expression for mass spectrometrists and 
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